European Heart Journal (2004) **25**, 1940–1965

ELSEVIER

EUROPEAN SOCIETY OF CARDIOLOGY

Special article

Clinical indications for cardiovascular magnetic resonance (CMR): Consensus Panel report☆

Dudley J. Pennell*, Udo P. Sechtem, Charles B. Higgins, Warren J. Manning, Gerald M. Pohost, Frank E. Rademakers, Albert C. van Rossum, Leslee J. Shaw, E. Kent Yucel

Cardiovascular Magnetic Resonance Unit, Royal Brompton Hospital, Sydney Street, London SW3 6NP, UK

Received 18 February 2004; revised 11 June 2004; accepted 24 June 2004

This paper was guest edited by Dr. E. Fleck. Deutsches Herzzentrum Berlin, Germany

Introduction

Cardiovascular magnetic resonance (CMR) is established in clinical practice for the diagnosis and management of diseases of the cardiovascular system. However, current guidelines for when this technique should be employed in clinical practice have not been revised since a Task Force report of 1998.[1] Considerable technical and practice advances have been made in the intervening years and the level of interest from clinicians in this field is at an unprecedented level. Therefore the aim of this report from a Consensus Panel of established experts in the field of CMR is to update these guidelines. As CMR is a multi-disciplinary technique with international interest, the Consensus Panel was composed of European and American cardiologists and radiologists with major input from members with additional established expertise in paediatric cardiology, nuclear cardiology, magnetic resonance physics and spectroscopy, as well as health economics. The Consensus Panel was originated, approved and funded in its activities by the Working Group on CMR of the European Society of Cardiology and the Society for Cardiovascular Magnetic Resonance.

The Consensus Panel recommendations are based on evidence compiled from the literature and expert experience. If there is insufficient evidence in the literature, this is indicated in the report but usually no recommendations are made under these circumstances. The appropriateness of using CMR is described for the frequent disease entities where imaging information may be warranted. The diagnostic use of CMR will be described in the context of other, competing imaging techniques, with particular emphasis on the differential indications with respect to echocardiography.

The usefulness of CMR in specific diseases is summarized by means of the following classification:
Class I = provides clinically relevant information and is usually appropriate; may be used as first line imaging technique; usually supported by substantial literature.
Class II = provides clinically relevant information and is frequently useful; other techniques may provide similar information; supported by limited literature.
Class III = provides clinically relevant information but is infrequently used because information from other imaging techniques is usually adequate.
Class Inv = potentially useful, but still investigational.

This classification is not meant to equate to AHA/ACC/ESC consensus documents. We have used the classification system that was used for the first consensus report,[1] with minor amendments in order to maintain parity with that report so that advances in the field can be readily identified. It should also be noted that the classification system for imaging technologies does not easily marry with that of therapeutic trials because the datasets are smaller, multicentre trials are unusual and randomized controlled trials the exception. In addition, the experience worldwide with the clinical applications of CMR is still limited.

It should also be noted that this consensus report reflects opinion at the start of 2004. The rapidly continuing technical and clinical advances in CMR will change the

☆ Endorsed by The Society for Cardiovascular Magnetic Resonance, and The Working Group on Cardiovascular Magnetic Resonance of the European Society of Cardiology.

* Corresponding author. Tel.: +44 20 7351 8810; fax: +44 20 7351 8816.
E-mail address: d.pennell@ic.ac.uk (D.J. Pennell).

0195-668X/$ - see front matter © 2004 Published by Elsevier Ltd on behalf of The European Society of Cardiology.
doi:10.1016/j.ehj.2004.06.040

indication's tables. Between formal reports, the consensus panel may post updates on the ESC CMR Working Group or SCMR websites.

Outline of CMR techniques

A brief description of the technical aspects of CMR is included here to facilitate understanding of the technical terms used in the clinical part of this report. It is necessarily brief and fuller texts give much greater detail.[2,3] A key point to understanding clinical CMR is that the interaction required for clinical imaging is at the level of the nucleus, which means that CMR is fundamentally safe and does not interfere with the electron shells involved in chemical binding (particularly in DNA) that can be altered by ionizing radiation such as X-rays. Only atomic nuclei with unpaired spin can exhibit the phenomenon of magnetic resonance as first described in 1946. Although this includes important elements such as carbon, oxygen, sodium, potassium and fluorine, these elements are rarely used for imaging in clinical practice. Phosphorus is used for clinical CMR spectroscopy, but the majority of clinical CMR interrogates the hydrogen nucleus which is abundant in water, fat and other biochemical compounds in the human body.

The hydrogen nucleus (a single proton), behaves as a small spinning magnet which aligns itself parallel to an external magnetic field and precesses about the field in the same way that a spinning top precesses in a gravitational field. The frequency of precession is 63 MHz for a field strength of 1.5 Tesla which is in the radiofrequency range. The ensemble of nuclei in a body region can be excited by radiowaves only at this resonant frequency, which has the effect of rotating the net magnetisation vector by an amount termed the *flip angle*. After this excitation, the net magnetization vector precesses around the direction of the main field, returning to its former position (*relaxation*). Whilst there is a component of magnetization perpendicular to the applied magnetic field, energy is transmitted as a radio signal and this can be received by a receiver coil placed over the chest. The return of the net magnetisation vector to equilibrium has two components: The vector component parallel to the main field returns to equilibrium by interacting with surrounding molecules which is a relatively slow process and is known as *T1 relaxation*. The vector component transverse to the field is more rapid and results from interaction between individual spins, and is termed *T2 relaxation*. CMR images can be weighted to show the distribution of T1 or T2, or just the density of protons. In order to localize the signals coming from the body, additional magnetic fields are required which are switched on and off at appropriate times; these are termed *gradient fields*. An MR image therefore simply represents the spatially resolved signal coming from the relaxing spins.

A CMR *scanner* has six major components. The *magnet*, which is usually superconducting, produces the static magnetic field whose strength is measured in Tesla. This field needs to be homogeneous and stable with time, and yet large enough to contain a human body. Resistive *gradient coils* within the bore of the magnet produce the gradient fields, and the currents within these coils are driven by the *gradient amplifiers*. The performance of the gradient system determines how fast magnetic resonance acquisition can be. A *radiofrequency coil* (antenna) is coupled to a *radiofrequency amplifier* to excite the patient with the radiofrequency pulses, and this (or another more localized surface coil) is coupled to the receiver to measure the signals coming from the patient. A *computer* is required to control the scanner and generate the images. Images are then displayed in static, dynamic (cine) modes or as multi-planar reconstructions.

An MR *pulse sequence* is a combination of radiofrequency pulses and magnetic gradient field switches, and can be considered as an orchestral score with multiple aspects of the scanner acting in concert and controlled by the scanning computer. For CMR, *spin echo*, *gradient echo*, *steady state free precession* (SSFP) and *echo-planar imaging* (EPI) sequences are the most commonly used for the signal read-out. Spin echo sequences are routinely used for multi-slice anatomical imaging and rapidly moving blood is typically displayed as black, whilst gradient echo and SSFP sequences are used for physiological assessment of function through cine acquisitions, and blood is typically white. Pre-pulses may be added to sequences and these may change the contrast appearances. For example, an *inversion recovery* prepulse is typically used for infarct/viability imaging, where myocardium is nulled to be black, infarct is white and blood is an intermediate grey. With modern scanners, many sequences are now performed during a 4—20 s breath-hold. This reduces image artefacts from respiratory motion. ECG gating is required for most CMR in order to coordinate the acquisition to the correct phases of the cardiac cycle.

Some specialized sequences exist which have particular application for the cardiovascular system. CMR angiography (MRA) is usually performed with three-dimensional (3D) coverage of the vessel during a short breath-hold and after intravenous injection of a *gadolinium*-based contrast agent. Gadolinium has seven unpaired electrons in its outer shell which hastens T1 relaxation, and usually thereby increases the signal in the area of interest. Non-contrast MR angiographic techniques are also sometimes used. Myocardial perfusion CMR follows the effect of a first pass of a bolus of intravenous gadolinium through multiple planes of the myocardium using ultrafast sequences such as Fast Low Angle Shot (*FLASH*), EPI or SSFP which can allow entire images to be acquired in <200 ms. For coronary CMR, some high resolution acquisitions cannot be completed within a breath-hold, and respiratory motion is reduced by using a *navigator*, whereby the diaphragm (or other interface) is monitored in real-time. In order to study regional myocardial contraction, a sequence called *tagging* may be used, which superimposes a grid of dark lines across the image in diastole. These tags subsequently deform through the cardiac cycle allowing the calculation of regional myocardial strain. Finally, *velocity mapping* is a sequence used to measure velocity and flow in blood vessels or within the heart somewhat

analogous to Doppler echocardiography, in which each pixel in the image displays the phase of the radiofrequency signal rather than its magnitude. The signal phase is encoded for velocity, and flow is calculated from the product of mean velocity and the vessel area measured throughout the cardiac cycle.

CMR is very safe and no long-term ill effects have been demonstrated. Claustrophobia may be problematic in about 2% of patients, but mild anxiolysis is often effective.[4] One of the most important safety issues for CMR is the prevention of introduction into the scanner area of ferromagnetic objects which can become projectiles. Metallic implants such as hip prostheses, prosthetic heart valves, coronary stents and sternal sutures present no hazard since the materials used are not ferromagnetic (although an artefact local to the implant may be present). Care is required in patients with many cerebrovascular clips however, and specialist advice is needed for such patients. Patients with pacemakers, implanted cardioverter defibrillators (ICD), retained permanent pacemaker leads and other electronic implants are not scanned, although some reports of success do exist,[5] and there is progress towards manufacture of CMR-compatible devices.

Congenital heart disease

General aspects

Evaluation of patients with congenital heart disease (CHD) is a significant strength of CMR because 3D contiguous data sets are very effective for the complete depiction of the pathological anatomy of both simple and complex CHD. Moreover, the lack of ionizing radiation is an important consideration when performing sequential studies in children and young adults. However, the clinical use of CMR depends on the age and the clinical condition of the patient. Sedation is required in small children and monitoring is demanding in critically-ill infants. Thus, CMR is usually performed following, and as an adjunct to, transthoracic echocardiography in neonates and infants. In contrast, CMR becomes the first line technique when in older children, in adolescents or adults, in more complex anatomy, or at any age after surgery because body habitus and interposition of scar tissue and lungs become an increasing problem for transthoracic echocardiography.[6,7] The need for and duration and risks of diagnostic catheterisation can be minimised by prior use of CMR.[6,8] Thus, diagnostic catheterisation is likely to become a one stage process with concurrent interventional procedures. Precise depiction of cardiac and arterial/venous great vessel anatomy using CMR should also decrease the duration and radiation dose associated with interventional procedures. In recent years, dual X-ray/CMR facilities have been proposed for more efficient diagnostic and interventional procedures during a single anaesthesia session.[9] Expertise in CMR is highly recommended in centres specialised in the care of patients with congenital heart disease.[6]

CMR techniques are generally less operator dependent than echocardiography, but a thorough understanding of the anatomic and functional principles of CHD is nevertheless required for a reliable study. This requires experience and training guidelines have been published.[10] All parts of the cardiovascular system can be imaged, a feature which makes a CMR evaluation especially useful in complex cases. For a complete CMR examination, the following sequences should be performed:

1. Anatomical images in the transaxial and at least one additional orthogonal plane (sagittal or coronal depending on the case). For thoracic aortic anomalies, additional oblique sections are acquired. Usually these are spin echo acquisitions.
2. Functional information with SSFP sequences in contiguous short axis planes for the evaluation of biventricular function, volumes, and mass.
3. When clinically indicated, measurements of velocity and flow volume in the heart and great vessels/conduits.
4. Gadolinium-enhanced MRA for 3D representation of the thoracic aorta, pulmonary arteries, and veins. For specific indications, it may also be employed for the 3D display of complex cardiovascular anatomy.

CMR may be used in the following specific congenital anomalies (see Table 1):

1. *Anomalies of the viscero-atrial situs*. The viscero-atrial situs (situs solitus, inversus, ambiguus) and malposition of the heart (dextrocardia, levocardia) are easily identified by conventional diagnostic methods. However, in the presence of additional lesions (atrioventricular or ventriculoarterial discordance, anomalous pulmonary or systemic venous connections) difficulties may arise in the definition of the topographic relation of the major cardiac segments. CMR provides anatomical data which is easily related to the surrounding structures of the body,[8] and thus provides reliable diagnoses with a sensitivity approaching 100%.[11] In patients with complex anomalies, especially in older patients, CMR may be the primary imaging technique so as to maximise non-invasive information prior to catheterisation.
2. *Anomalies of the atria and venous anomalies*. CMR may be valuable in the assessment and identification of atrial septal defects. Quantification of shunt size (pulmonary to systemic flow ratio) by CMR compares favourably to other imaging techniques and should be considered a primary method.[12] The best technique for assessing the interatrial septal morphology is transesophageal echocardiography (TEE).[13] In infants, CMR may be used as a second line technique following transthoracic echocardiography. A drawback of echocardiography is the difficulty of evaluating anomalous pulmonary venous return. CMR appears to be the best non-invasive technique for the evaluation of pulmonary veins,[14,15] as complete and selective demonstration may not be achieved by echocardiography or X-ray angiocardiography.[16] CMR may also be indicated to identify partial anomalous venous return in patients with atrial septal defects.[17] CMR may identify atrial septal defect (ASD) or partial anomalous pulmo-

Table 1 Indications for CMR in congenital heart disease

Indication	Class
General indications	
1. Initial evaluation and follow-up of adult congenital heart disease	I
Specific indications	
1. Assessment of shunt size (Qp/Qs)	I
2. Anomalies of the viscero-atrial situs	
Isolated situs anomalies	II
Situs anomalies with complex congenital heart disease	I
3. Anomalies of the atria and venous return	
Atrial septal defect (secundum and primum)	II
Anomalous pulmonary venous return, especially in complex anomalies and cor triatriatum	I
Anomalous systemic venous return	I
Systemic or pulmonary venous obstruction following intra-atrial baffle repair or correction of anomalous pulmonary venous return	I
4. Anomalies of the atrioventricular valves	
Anatomic anomalies of the mitral and tricuspid valves	II
Functional valvular anomalies	II
Ebstein's anomaly	II
Atrioventricular septal defect	II
5. Anomalies of the ventricles	
Isolated ventricular septal defect	III
VSD associated with complex anomalies	I
Ventricular aneurysms and diverticula	II
Supracristal VSD	I
Evaluation of right and left ventricular volumes, mass and function	I
6. Anomalies of the semilunar valves	
Isolated valvular pulmonary stenosis and valvular dysplasia	III
Supravalvular pulmonary stenosis	II
Pulmonary regurgitation	I
Isolated valvular aortic stenosis	III
Subaortic stenosis	III
Supravalvular aortic stenosis	I
7. Anomalies of the arteries	
Malpositions of the great arteries	II
Post-operative follow-up of shunts	I
Aortic (sinus Valsalva) aneurysm	I
Aortic coarctation	I
Vascular rings	I
Patent ductus arteriosus	III
Aortopulmonary window	I
Coronary artery anomalies in infants	Inv
Anomalous origin of coronary arteries in adults and children	I
Pulmonary atresia	I
Central pulmonary stenosis	I
Peripheral pulmonary stenosis	Inv
Systemic to pulmonary collaterals	I

nary venous connection in adults with right-sided chamber enlargement, hypertrophy or dysfunction of unknown aetiology. CMR may be particularly useful for demonstrating pulmonary venous stenoses or occlusions post-operatively, or after ablation.[18] It is effective for demonstrating stenoses of intra-atrial baffles after repair of transposition of the great arteries.[19] Moreover, systemic venous anomalies (bilateral superior cava, interrupted inferior cava) are correctly identified by CMR.[20]

3. *Anomalies of the atrioventricular connections*. CMR is an excellent technique for defining the morphologic features of each atrium and ventricle.[8] Consequently, it can demonstrate discordant atrioventricular connections and crisscross atrioventricular connections.[21] CMR is also indicated for demonstrating double inlet ventricle,[22] straddling atrioventricular valve, tricuspid atresia, and mitral atresia. Echocardiography is usually employed initially for these abnormalities and CMR is used to supplement this information. CMR is superior to echocardiography for quantifying ventricular volumes in these abnormalities which may be critical for surgical decisions regarding biventricular repair versus the Fontan procedure.
4. *Anomalies of the ventricles*. CMR is highly sensitive and specific for the quantification and detection of ventricular septal defects,[23,24] and detection and localisation of jets is helpful.[25] However, CMR may add little anatomical information in isolated ventricular septal defect when the diagnosis is already established by echocardiography, except that CMR can readily quantify shunt volume.[12] This may become more relevant if clinicians come to rely on noninvasive diagnostic information prior to surgery. CMR has an important role in depicting ventricular anatomy in complex anomalies such as in tetralogy of Fallot, pulmonary atresia, tricuspid atresia, and univentricular hearts.[9,26] CMR can precisely depict the location of the ventricular septal defect in relation to the great arteries in double outlet ventricles.[27] CMR is the most accurate technique for quantifying left and right ventricular mass and volumes.
5. *Valves*. Echocardiography is the primary imaging modality for defining valve morphology, and estimating valvular regurgitation. However, CMR velocity mapping can quantify the severity of regurgitation in many cases, and this is valuable for sequential monitoring of the severity of pulmonary regurgitation after outflow patch surgery for tetralogy of Fallot,[28] and after placement of RV to pulmonary artery conduits.[29] Thus, CMR may be useful for decision making on valve replacement. CMR has also been shown to be effective for the morphologic depiction of tricuspid atresia and Ebstein's anomaly.[30] Moreover, it can provide a precise RV volumetric and functional assessment in these anomalies.[31]
6. *Anomalies of the great arteries and conduits*. CMR is very effective for the evaluation of anomalies of the thoracic aorta. Although 2D echocardiography with Doppler is usually sufficient to diagnose and estimate the haemodynamic severity of coarctation of

the aorta in infants, difficulties may be encountered in older children or adults. Under these circumstances the severity and extent of stenosis including diffuse narrowing of the aortic arch, the collateral circulation as well as the shape and size of the ascending aorta can be demonstrated by CMR. Velocity mapping can estimate the pressure gradient across the coarctation and the volume of collateral flow.[32,33] Thus, CMR is now regarded as the optimal modality for the evaluation of coarctation of the aorta. CMR is also the procedure of choice for evaluation of coarctation after surgery or angioplasty.[34,35,36] CMR is also useful for the evaluation of sinus of Valsalva aneurysm, aortic dilatation, aneurysm associated with Marfan and Ehler-Danlos syndromes, and in the general monitoring of aortic dimensions over time. CMR is the procedure of choice for the diagnosis of aortic arch anomalies (vascular rings).[37,38] In infants, visualisation of a patent ductus arteriosus is commonly achieved by echocardiography. CMR has a role in older patients and is often better suited to depict the lesion.[39] In patients, in whom an aortopulmonary window is suspected, CMR may be helpful to establish the differential diagnosis or demonstrate the additional defect.

CMR is also valuable in the visualisation of the pulmonary artery and its main branches, which is essential in the surgical management of patients with diminished pulmonary artery blood flow. Echocardiography may often be limited due to reflection of the ultrasound by the chest wall and lungs. Angiocardiography can be dangerous in cyanotic children, as very small pulmonary arteries may be difficult to catheterise and non-confluent vessels may not be seen even with pulmonary venous wedge X-ray angiography. The blood supply to the lungs in patients with tetralogy of Fallot and pulmonary atresia is well defined by CMR.[40–43] MRA is the most effective non-invasive technique for demonstrating systemic to pulmonary collateral vessels.[44] MRA is also indicated for demonstrating the status of the pulmonary vessel after shunt,[45] or unifocalization procedures. Both before and after surgery, CMR, especially 3D gadolinium MRA, is indicated for demonstrating stenoses of the central,[46] and segmental pulmonary arteries.[47] The severity of stenoses of the central pulmonary arteries can be estimated using velocity mapping to measure flow separately in the right and left pulmonary arteries.

CMR is valuable to assess the patency of systemic-to-pulmonary shunts and extracardiac conduits.[48–51] Patients with extracardiac ventriculopulmonary shunts often experience graft degeneration and echocardiographic imaging is difficult due to the retrosternal position of the graft. CMR provides accurate anatomic and functional information and is the technique of choice for following these patients.[52]

7. *Post-operative CHD*. Echocardiography is usually employed for the serial evaluation of most CHD patients after transcatheter or surgical treatment. The sequential monitoring of ventricular dimensions and function is important during follow-up. CMR provides more precise and reproducible quantification of ventricular volumes, mass and function than 2D echocardiography.[53,54] This is especially the case for the RV,[55] which is usually the chamber implicated in and stressed by repair of CHD.[29,56] Sequential measurements of RV volumes, mass and function are important for post-operative management after intra-atrial repair of transposition and repair of tetralogy of Fallot,[57] and other abnormalities requiring pulmonary transannular patch or conduit insertion. The consequences of pulmonary regurgitation on RV and left ventricular (LV) function can be comprehensively evaluated by the combined use of volume measurements and assessment of diastolic ventricular function by velocity mapping CMR.[58] This unique information may have prognostic and therapeutic implications for the management of patients with (repaired) CHD. Pulmonary blood flow and regurgitant volume can also be measured in the presence of some stents.[59] CMR is indicated for evaluation of the morphology and function after repair of complex congenital heart disease and during the stages of various surgical repairs, such as those used for hypoplastic left heart syndrome,[60] and single ventricle.[61]
8. *Adult CHD*. CMR and TEE are complementary for the evaluation of adult CHD.[6] The limited field of view and sometimes inadequate acoustic window renders echocardiography less effective in adults. Compared to echocardiography, CMR tends to be better for the evaluation of the morphology of abnormalities of the aorta, pulmonary arteries, and pulmonary veins and for quantification of RV function and blood flow. It is also indicated when the quality of echocardiographic images is limited and interpretation is ambiguous.
9. *Coronary artery anomalies*. CMR is useful in defining congenital or inflammatory changes of the coronary arteries as in Bland-White-Garland syndrome,[62] and Kawasaki disease.[63–65] Congenital abnormalities in the course of the proximal coronary arteries can be reliably depicted by CMR both in patients with CHD (prevalence of 30% in CHD),[66] and especially tetralogy of Fallot,[67,68]and also in those with otherwise normal cardiac anatomy (1% of the general population).[69–71] CMR has advantages over X-ray angiography in clarifying the spatial relationship of these arteries with respect to the aorta and the pulmonary artery, which is crucial for estimating the risk associated with these abnormalities and for surgical planning.

Acquired vascular disease

CMR is well-established for evaluation of a wide variety of acquired vascular diseases. CMR is particularly useful for vascular lumen imaging with its ability to generate projection angiograms (MRA). These can be generated either with time-of-flight techniques, or with intravenous gadolinium, which has similar pharmacokinetic properties to iodinated X-ray contrast but with the advantage of minimal nephrotoxicity. Consequently, it is well-suited for use in patients with contraindications to X-ray contrast (allergy, renal insufficiency). In addition to angiography, the wide variety of soft tissue con-

trast available on CMR (proton density, T1, T2, lipid-saturation) can be applied to vascular imaging to assess features of vessel wall such as haematoma/thrombus, inflammation, and atherosclerotic plaque. In addition to morphologic imaging of blood vessels, velocity mapping can be used to assess and measure the blood flow. Blood velocity and flow can be integrated across the cardiac cycle and the vessel lumen for reliable volume flow measurements (see Table 2).

Aorta

For the thoracic and abdominal aorta, CMR accurately displays the size, extent, and shape of aneurysms.[72] Multi-planar imaging is helpful in tortuous segments to evaluate and follow cross-sectional diameters and areas as well as to assess the relationship of the aneurysm to major branch vessels. Both black-blood and white-blood imaging can be used to differentiate patent lumen from intraluminal thrombus.[73] Gadolinium MRA is a necessary adjunct for visualizing any associated branch-vessel occlusive disease or relationship of the aneurysm to smaller vessels.[74]

Flow-sensitive imaging cannot be relied upon in the setting of aneurysmal disease due to the stagnant flow patterns that may be present and gadolinium MRA is more robust. Post-gadolinium T1-weighted CMR, especially with fat saturation, is helpful in identifying areas of peri-aortic inflammation in mycotic aneurysms.[75–77] Inflammatory abdominal aortic aneurysms can have a thick rind of tissue encircling the anterior and lateral aspects of the aorta, which typically enhances with gadolinium.[78] Although not as widely used as CT for pre- and post-operative evaluation of aortic stent-grafts, CMR provides comparable information with regard to pre-stent anatomy and post-stent leaks.[79] The only limitation of CMR in this setting is its inability to visualize calcium, which is important for stent graft planning. For this purpose, it can be supplemented with non-contrast computed tomography (CT).

Aortic dissection is a well-established indication for CMR, and accuracy is very high.[80–82] With increasing ability to monitor acutely ill patients in the CMR suite combined with advances in imaging speed, CMR is competitive with CT for speed of diagnosis of aortic dissection.[83] However, scanner availability and location may limit the utility of CMR in the acute setting. The intimal flap can be demonstrated and staging with regard to involvement of the ascending aorta and branch vessel involvement can be made.[82] Gadolinium MRA is typically acquired in the aortic long-axis plane and reformatted into the axial plane for definition of the intimal flap and branch vessel involvement. Associated aortic regurgitation can be detected with cine gradient echo CMR and quantified using velocity mapping.[84] Pericardial fluid is also easily identified and characterised.[85] CMR is ideal for measuring aortic diameter and intimal flaps in the chronic setting, making it ideal for evaluation and follow-up of patients following surgery,[86] and those with Marfan's syndrome.[87] Compared with CT, CMR avoids radiation exposure, an especially important consideration in children. When compared with transthoracic echocardiography, CMR should be considered as the first line technique in Marfan's syndrome for imaging the aorta, because CMR is capable of visualising its entire length.

Intramural haematoma is a variant of dissection, where the false channel in the aortic wall is filled with thrombus. Dissections can include segments of both patent false lumen and intramural haematoma in the same patient, depending on the location of intimal tears, pressure in the false lumen and stage of dissection development.[88] Flow-sensitive techniques are less accurate for the diagnosis of intramural haematoma,[89] and more useful is spin echo imaging with T1 weighting which can detect red cell breakdown products (methaemoglobin) as a bright signal within the aortic wall in the acute and subacute stages. The use of fat saturation is helpful for distinguishing haematoma within the aortic wall from the surrounding mediastinal fat.[90] Penetrating ulcers are a form of dissection where there is intimal erosion with either ulceration extending into the media and/or focal intramural haemorrhage.[91] Penetrating aortic ulcer is associated with more extensive atherosclerosis, ectasia, older age but less severe hypertension than typical aortic dissection. CMR shows focal ulcerated atherosclerotic

Table 2 Indications for CMR in acquired diseases of the vessels

Indication	Class
1. Diagnosis and follow-up of thoracic aortic aneurysm including Marfan disease	I
2. Diagnosis and planning of stent treatment for abdominal aortic aneurysm	II
3. Aortic dissection	
Diagnosis of acute aortic dissection	II
Diagnosis and follow-up of chronic aortic dissection	I
4. Diagnosis of aortic intramural haemorrhage	I
5. Diagnosis of penetrating ulcers of the aorta	I
6. Pulmonary artery anatomy and flow	I
7. Pulmonary emboli	
Diagnosis of central pulmonary emboli	III
Diagnosis of peripheral pulmonary emboli	Inv
8. Assessment of thoracic, abdominal and pelvic veins	I
9. Assessment of leg veins	II
10. Assessment of renal arteries	I
11. Assessment of mesenteric arteries	II
12. Assessment of iliac, femoral and lower leg arteries	I
13. Assessment of thoracic great vessel origins	I
14. Assessment of cervical carotid arteries	I
15. Assessment of atherosclerotic plaque in carotid artery/ aorta	III
16. Assessment of pulmonary veins	I
17. Endothelial function	Inv

plaque on gadolinium MRA, and/or focal intramural haematoma, best seen on T1-weighted images with fat saturation.[92] Ulceration may also be seen as an incidental, benign finding in asymptomatic elderly patients with no or atypical symptoms and is not a cause for concern.[93]

There has been recent interest in the use of CMR for the detection of potentially embologenic aortic plaque.[94] Both gradient echo or double inversion-recovery black-blood scans define aortic plaque and can monitor progression.[95] There is good correlation between TEE and double inversion-recovery black-blood CMR for aortic plaque characterisation and thickness.[96] A potential limitation of CMR is the identification of highly mobile plaques, which may move asynchronously with the cardiac cycle. The real-time feature of echocardiography may be advantageous for fully characterizing plaque mobility. On the other hand, CMR may be superior to echocardiography for detecting plaques in the aortic arch. CMR may be able to replace the more invasive TEE for this application if confirmed in larger studies.

Pulmonary arteries

The most common acquired disease of the pulmonary arteries is pulmonary embolism. Promising results have been obtained in several small series using gadolinium MRA.[97,98] However, these scans currently require prolonged breath-holds which may be difficult to reliably achieve in this population. For this reason, as well as improved spatial resolution and access, CT remains the study of choice at many centres. MRA may be useful in patients with contraindications to X-ray contrast. Although rarer, pulmonary artery aneurysms[99] and dissections[100] can also be evaluated by CMR.

Extremities

The primary indication for CMR of the lower extremities is assessment of suspected atherosclerotic occlusive disease. While time-of-flight imaging is well-validated for imaging of the tibial and pedal vessels,[101] it has been supplanted by 3D gadolinium MRA for inflow (aorta, iliac, femoral, popliteal) evaluation.[102] Imaging of the tibial vessels using the bolus-chase approach may be compromised by venous contamination. One straightforward solution to this problem is to image the calves with an initial injection, followed by two-station bolus-chase of the pelvic and thighs. The pedal vessels can also be imaged with gadolinium MRA, although it may be difficult to integrate a dedicated pedal contrast-enhanced scan into a full lower extremity study due to contrast limitations.[103] For limb-threatening ischaemia, gadolinium MRA has been validated for the evaluation and pre-interventional planning of peripheral occlusive disease.[104] CMR may also be used to identify patients who may be suitable for directed endovascular interventions There has been much less experience with imaging of the upper extremity. Gadolinium MRA works well for the great vessel origins from the aortic arch out to the axillary artery.[105] Beyond that, time-of-flight imaging may be used with the arms positioned over the head. Gadolinium MRA has also been used for the vessels of the hand with promising results.[106]

Renal and mesenteric arteries

Gadolinium MRA is the dominant approach for the renal and mesenteric vessels due to its reproducibility, ease of use, and efficacy.[107,108] Limitations include lower spatial resolution than X-ray angiography, which remains better for quantitative stenosis measurement as well as evaluation of branch vessels and small accessory vessels. For this reason, X-ray angiography may be preferred for renal donor evaluation. On the other hand, MRA may provide more information about venous anomalies, which may be important in patients undergoing laparoscopic nephrectomy. Adjunctive imaging with either time-of-flight or phase-contrast imaging may be performed to provide additional imaging information about the renal arteries. In particular, dephasing effects seen at areas of stenosis using 2D MRA may provide qualitative information about the haemodynamic significance of lesions. CMR remains complementary to captopril renal scintigraphy and duplex Doppler evaluation of resistive index. The former provides a non-invasive arterial map, while the latter provides highly quantitative information about renal perfusion and function under conditions of stress. Several approaches to functional imaging with CMR have been described;[109] none have achieved the level of acceptance of nuclear medicine renal functional evaluation.

Published experience with mesenteric gadolinium MRA is limited. Experience suggests similar results as for renal angiography and gadolinium MRA provides excellent images of the proximal mesenteric vessels for screening for atherosclerotic occlusive disease.[110] Velocity mapping of the superior mesenteric artery and vein after a fatty meal challenge may be helpful for providing information about the functional significance of mesenteric occlusive disease. For more distal or detailed evaluation, X-ray angiography is currently still required.

Extracranial carotid arteries

Carotid CMR angiography using 3D time-of-flight is as accurate as X-ray angiography for measurement of internal carotid stenosis.[111] Rapid screening of the carotid arteries for clinically significant occlusive disease can be performed using 2D time-of-flight MRA. Gadolinium MRA has been limited by the rapid jugular venous return which obscures the carotid bifurcation, but this can be improved by high temporal resolution imaging with lower spatial resolution during the arterial phase and high resolution with contrast encoding (centre of k-space) heavily weighted toward the start of the acquisition (elliptical centric). Published data has shown results with gadolinium MRA that is comparable to 3D time-of-flight MRA.[112] Advantages of gadolinium MRA include speed,

improved coverage in the superior-inferior direction, including the arch origins, and higher sensitivity to slow flow in carotid pseudo-occlusion.

Arterial wall imaging

The arterial wall is affected with atherosclerosis long before clinical manifestations,[113] and this provides an opportunity for early detection of CAD prior to irreversible clinical consequences. Because atherosclerosis is a systemic disease, CMR can be used to image arteries outside of the heart such as the carotid and aorta.[114–116] Arterial wall CMR identifies the plaque burden and plaque constituents using a combination of T1, T2 and proton density weighted images.[117–119] This has allowed the imaging of the cholesterol pool component,[120] which is believed to significantly influence the likelihood of plaque rupture. In addition, the fibrous cap can be identified,[121] and thin or disrupted caps have been linked with cerebrovascular events.[122] Contrast agents have been used to further characterize plaque, show inflammation,[123,124] neovasculature,[125] and the fibrous cap.[126] Longitudinal study of the plaque by CMR has been used to gauge the effectiveness of anti-atheroma therapy such as statin treatment, showing reduction in plaque volume,[127,128] and the lipid pool.[129] More recently, coronary wall CMR has been reported, and wall thickening and plaque constituents have been identified.[130–133]

Brachial artery reactivity

Endothelial function can be examined non-invasively with stimuli which cause arterial vasodilation. Flow mediated dilation is used to examine endothelial function directly, by occluding usually the forearm using a blood pressure cuff inflated above systolic pressure for a standard time period. On release of the cuff, reactive hyperaemia causes increased endothelial shear and the release of nitric oxide (NO) which causes the brachial artery to dilate. Endothelial independent responses can also be tested by using glyceryl trinitrate, typically as a sublingual spray. Visualisation of brachial dilation with these stimuli was first described using ultrasound,[134] but it may be difficult to ensure that the transducer is correctly positioned perpendicular to the artery and without movement, and that repeated measurements are made with good reproducibility. CMR techniques are considered to have advantages in both these areas and comparisons of CMR and ultrasound for accuracy and reproducibility favour CMR.[135] In addition to measuring brachial dilation, CMR can also measure flow changes directly in response to the standard stimuli.[136,137]

Coronary artery disease

CMR has opened new avenues for assessing coronary artery disease (CAD) and its consequences. It provides valuable information which may not be available from other diagnostic tools such as echocardiography and nuclear cardiology which currently dominate non-invasive diagnosis in patients with CAD (see Table 3).

Assessment of ventricular function and mass

CMR is accurate, reproducible and well validated for measuring LV and RV volumes and mass; this makes it valuable for the assessment of fundamental parameters of cardiac function as well as longitudinal follow-up of patients over time. The absolute accuracy of global LV volume measurements, with a 3D approach that has no geometric assumptions, has been established ex vivo.[138,139] In vivo accuracy of LV volume measurements is more difficult to prove, but validation work strongly suggests that CMR is accurate by 2 methods: First by showing equivalence in normal human subjects of the stroke volumes measured by the 3D contiguous slices approach of the LV and RV which must be equivalent in normals;[138,140,141] and second by using flow mapping,[142–144] to show equivalence of LV stroke volume and aortic flow.[144,145] RV volumes have likewise been validated *in vitro*,[146] and *in vivo*.[141] The accuracy of LV mass,[147] has been established directly compared with autopsy hearts from humans,[148,149] and animals.[150–154] The accuracy of RV mass measurements has also been established in ex vivo animal hearts.[155–157] Comparisons of CMR with echocardiography and scintigraphy are useful for guiding clinical interpretation, but are less useful for absolute validation because they show wide individual discrepancies in results compared with CMR because of their lower accuracy.[158]

The interstudy reproducibility of CMR-derived quantitative parameters of ventricular function and mass is excellent for both the LV,[53,159–163] and RV,[55] and has

Table 3 Indications for CMR in coronary artery disease

Indication	Class
1. Assessment of global ventricular (left and right) function and mass	I
2. Detection of coronary artery disease	
Regional left ventricular function at rest and during dobutamine stress	II
Assessment of myocardial perfusion	II
Coronary MRA (CAD)	III
Coronary MRA (anomalies)	I
Coronary MRA of bypass graft patency	II
MR flow measurements in the coronary arteries	Inv
Arterial wall imaging	Inv
3. Acute and chronic myocardial infarction	
Detection and assessment	I
Myocardial viability	I
Ventricular septal defect	III
Mitral regurgitation (acute MI)	III
Ventricular thrombus	II
Acute coronary syndromes	Inv

been shown to be considerably superior to 2D and m-mode echocardiography.[55,149] This allows the reduction of sample sizes in drug studies.[162,163] Phase 2 trials and sub-studies in phase 3 trials are being conducted using CMR as primary endpoints.[164,165]

Regional contractile function is also well-assessed by CMR with visual inspection of cines or quantification of wall motion and thickening for both the RV,[166,167] and LV.[168–171] However, the CMR tagging technique permits the determination of the strain of the myocardium as a measure of contractility,[172] By monitoring the progressive distortion of the tags during the course of the cardiac cycle, regional ventricular strain myocardial rotational deformation, ventricular non-uniformity, and differences in endocardial and epicardial wall motion can be calculated.[173] This can be fully resolved in 3D to cover the entire heart.[174] CMR tagging has been validated against invasive sonomicrometer studies,[175] and has been used to discriminate infarcted from remote myocardium.[176]

Detection of coronary artery disease

There are several approaches to detecting CAD using CMR. These include the visualization of the effects of induced ischaemia (wall motion, perfusion) and direct visualization of coronary arteries (coronary angiography and flow). Early detection of atherosclerosis and endothelial dysfunction is also possible (arterial wall imaging, brachial artery reactivity).

Stress wall motion abnormalities

Physical exercise within the magnet leads to degradation of image quality from motion artefacts, and therefore pharmacologic stress is more commonly used. Dobutamine is ideal for this,[177–180] with superior results compared with dipyridamole.[181–185] Dobutamine stress CMR is well established as a technique for identifying ischaemia-induced wall motion abnormalities in CAD, with guidelines for clinical practice.[186] Breath-hold gradient echo or SSFP cines are used to examine regional wall function throughout the LV before and during stress. Diagnostic results are very good and direct comparison data with dobutamine stress echocardiography have shown superiority of CMR,[187] due to higher quality imaging.[188] Dobutamine stress CMR has been shown to be very effective in the diagnosis of CAD in patients who are unsuitable for dobutamine echocardiography.[189] Quantification of LV wall motion and thickening using CMR using the centreline method may improve the accuracy for detection of patients with single vessel CAD.[190] There is a low event rate when dobutamine CMR is normal,[189,191,192] and a higher event rate in the presence of ischaemia.[191] CMR has also been used for pre-operative risk assessment.[193]

Other CMR techniques have been used to assess CAD during dobutamine. Tagging methods[194,195] have shown increased sensitivity for diagnosis of CAD.[192] Objective analysis using tagging would be expected to reduce observer interpretation variability, which is well recorded for dobutamine stress echocardiography,[196] and application of this CMR technique in a large clinical trial is awaited. In the MR environment, the ECG is uninterpretable with regards to STT wave change. Real-time CMR may be used to monitor wall motion and may eliminate the need for breath-holding.[197] Diastolic function has been shown to be abnormal using dobutamine CMR in CAD,[198,199] and parameters of global ventricular function such as flow acceleration are affected by dobutamine-induced ischaemia.[200] Further work is required to determine the clinical role of these techniques.

Myocardial perfusion

Myocardial perfusion CMR now achieves comprehensive ventricular coverage using multi-slice imaging in contiguous short axis, or mixed short and long axis planes. An intravenous bolus of gadolinium contrast agent (up to 0.1 mmol/kg) is given usually in the antecubital fossa with a power injector to allow a fast and consistent injection rate (typically 5–7 mL/s). Ideally, imaging is performed on every ventricular plane with each cardiac cycle. Visual interpretation to identify dark areas of low perfusion may be performed, or the myocardial signal may be measured during the first pass for computer analysis. Quantification can be performed by measuring the upslope of myocardial signal increase and the plotting of colour parametric perfusion maps.[201,202] More complex analysis includes respiratory motion correction,[203] and deconvolution analysis allowing for the input function from the LV blood pool signal curve,[204] in order to generate regional values for quantitative perfusion index and myocardial perfusion reserve. These techniques have been extensively reviewed,[205,206] and validated in animal models.[207–209] In humans in vivo, validation against perfusion reserve and absolute blood flow by PET has been performed.[202]

For clinical application, CMR perfusion is still in development, and two clinical scenarios are being tested. First, the simple approach of assessing stress myocardial perfusion only during vasodilation, and using late gadolinium enhancement to define areas of non-viability. Second, is the use of both stress and rest myocardial perfusion scans, which is more akin to conventional nuclear cardiology procedures, and has the benefit of allowing the generation of myocardial perfusion reserve measurements.[210,211] In clinical studies for the detection of CAD, the results of myocardial perfusion CMR are very good in comparison with X-ray coronary angiography, [201,202,212] PET,[202] and SPECT.[201] CMR has shown improvement in myocardial perfusion reserve after coronary angioplasty,[213] reduced perfusion in hypertrophic cardiomyopathy,[214] and impaired subendocardial perfusion in cardiac syndrome-X.[215] A technique called T2* blood oxygen level dependent (BOLD) has also recently been described, which allows measurement of myocardial perfusion without the use of a contrast agent.[216–219] The clinical role of the BOLD technique is promising,[220] but not yet fully defined.

Coronary angiography and flow

MRA is used routinely for evaluation of the arteries and veins throughout the body, but coronary MRA is techni-

cally more difficult due to their small size, tortuosity, complex 3D anatomy, and near incessant cardiac and respiratory motion. Using 3D acquisitions and modern optimized sequences, both breath-hold,[221] and navigator techniques,[222] have been used. A multi-centre trial has shown 81% negative predictive value for the exclusion of multi-vessel proximal CAD.[223] However, the current spatial resolution and residual motion during the acquisition period, restricts the assignment of diameter stenosis severity to broad categories, and distal vessel assessment of run-off for surgical planning is still problematic. The application of coronary MRA for the assessment of the course of anomalous coronary arteries is well established however, and is usually undertaken after X-ray angiography to ensure that the proximal portion does not have a malignant course between the aorta and pulmonary artery.[66,69–71] A different approach to detecting CAD by CMR is the noninvasive measurement of coronary flow velocities.[224,225] Determination of coronary flow by CMR at rest and after adenosine has been reported in animals,[226] and in humans.[227–229] The use of coronary flow reserve in humans has been reported for identifying stenosis of the left anterior descending artery,[230] and in-stent restenosis.[231]

CMR sequences can also be used to image coronary vein grafts. Both spin echo,[232,233] and gradient echo imaging,[234,235] yield accuracies in predicting graft patency of around 90%. This may prove useful in early post-operative chest pain syndromes in order to exclude graft occlusion. Bypass graft flow has proved useful in identifying diseased vein grafts through reduced baseline flow and flow reserve.[236–238] and may further define focal stenoses.[239–241]

Assessment of chronic coronary syndromes

Myocardial infarction (MI) can be detected with high accuracy and sensitivity using late gadolinium-enhanced CMR.[242] Gadolinium (0.1–0.2 mmol/kg) is given intravenously and after 10–20 min, CMR is commenced using an inversion recovery sequence, where the inversion time is chosen to null myocardial signal. Because normal myocardium is uniformly tightly packed with muscle, and gadolinium is an extracellular contrast agent, there is uniformly low signal in the normal heart. In areas of MI, the extracellular compartment is expanded, and in addition, gadolinium wash out from these areas is slow. This leads to a higher gadolinium concentration on the late enhancement scan, which shows as bright signal, and has lead to the aphorism ''bright is dead''. Because CMR has high resolution, it is possible to determine the transmural distribution resolution of MI in vivo. The technique has been extensively validated in animal MI models,[243–246] and has now replaced other CMR techniques for detecting MI. In humans, late gadolinium enhanced CMR has been shown to accurately detect both Q-wave and non-Q wave MI.[247] Because the technique is so sensitive, CMR has been shown to identify sub-endocardial MI when wall motion and perfusion by SPECT are normal.[248]

In the assessment of myocardial viability for the clinical scenario of consideration of bypass surgery for improvement of LV function, CMR has been shown to be very useful. As CMR accurately measures wall thickness, which is reduced in chronic transmural MI,[249] this has been used to exclude the presence of viable myocardium in chronic infarcts with good correlation to positron emission tomography (PET) findings using fluorodeoxyglucose (FDG).[250] In dysfunctional areas where wall thickness is preserved, viability can be established by demonstrating improved thickening during low-dose dobutamine infusion, and again correlation with FDG-PET is good.[250] Late gadolinium-enhanced CMR has also been tested for prediction of viability,[251] and when the transmural extent of infarction is <50%, the likelihood for functional recovery in acute MI,[252] or with bypass surgery is good.[253] Reproducibility is good,[254] direct comparisons with PET are excellent,[255,256] and CMR has been shown to be superior to thallium SPECT.[257]

Evaluation of acute coronary syndromes

CMR has been used in the emergency room in the assessment of chest pain.[258] CMR showed a sensitivity and specificity of 84% and 85% for identifying patients with CAD, and multi-variate analysis including standard clinical tests (ECG, troponin, TIMI risk score) showed that CMR was the strongest predictor of CAD and added diagnostic value over clinical parameters, including identification of enzyme-negative unstable angina. This promising data needs to be confirmed in other centres.

CMR also identifies microvascular obstruction in acute MI.[259,260] This is demonstrated early (1–2 min) after intravenous injection of gadolinium. At this time, which is well before late gadolinium-enhancement CMR would be performed, inversion recovery CMR shows areas within the MI which have severely compromised perfusion as black, and this indicates areas with microvascular collapse. Microvascular obstruction detected by CMR has been linked to ventricular remodelling,[261] and adverse cardiovascular events.[262] Finally, the transmural extent of late gadolinium-enhancement CMR predicts recovery of function following acute MI.[263]

CMR is effective in demonstrating the complications of acute MI including ventricular aneurysm,[264] pseudoaneurysms,[265] ventricular septum perforation,[266] and mitral regurgitation. As echocardiography may yield false positive and false negative results when looking for LV thrombi in post-infarction patients,[267] CMR is useful.[268–270]

Cardiomyopathies and cardiac transplantation

The cardiomyopathies include a variety of diseases where the primary pathology directly involves the myocardium excluding CAD. CMR is proving increasingly

valuable in the identification and management in these conditions (see Table 4).

Hypertrophic cardiomyopathy

Clinically, hypertrophic cardiomyopathy (HCM) requires an accurate diagnosis, determination of the distribution of hypertrophy and its functional consequences, and assessment of the likelihood of sudden death and progression to heart failure. Two-dimensional and Doppler echocardiography are the most commonly used non-invasive methods to study HCM.[271,272] However, the 3D nature of CMR allows for the precise definition of the site and the extent of hypertrophy, especially at the LV apex which may not be well assessed by echocardiography,[273] which can lead to underdiagnosis of apical HCM.[274] Cardiac function and flow dynamics of the outflow tract are also well characterised by CMR.[275–277] CMR myocardial tagging identifies abnormal patterns of strain, shear and torsion in HCM, demonstrating significant dysfunction in hypertrophic areas.[278–280] Late enhancement gadolinium CMR has also been used in HCM to demonstrate areas of fibrosis,[281] and the extent of this abnormal uptake is linked to the risk of sudden death and development of LV dilation and heart failure.[282] CMR has also been used to identify the functional and anatomical consequences of septal resection,[283] and percutaneous ablation.[284] Serial CMR therefore permits complete assessment of the morphologic and functional consequences of the disease, is ideal for screening of relatives of probands because of its phenotypic accuracy, and its ability to identify abnormal myocardial substrate linked to adverse events. Therefore, especially in patients in whom echocardiography is technically unsatisfactory, CMR should be considered the technique of choice for diagnosing and following patients with all variants of HCM. Finally, it is now known that about 4% of patients who present clinically with HCM actually have Fabry's disease. Gadolinium enhanced CMR shows unusual lateral wall enhancement in these patients,[285] and further work is required to evaluate this finding.

Table 4 Indications for CMR in patients with pericardial disease, cardiac tumours, cardiomyopathies, and cardiac transplants

Indication	Class
1. Pericardial effusion	III
2. Constrictive pericarditis	II
3. Detection and characterization of cardiac and pericardiac tumours	I
4. Ventricular thrombus	II
5. Hypertrophic cardiomyopathy	
Apical	I
Non-apical	II
6. Dilated cardiomyopathy	
Differentiation from dysfunction related to coronary artery disease	I
7. Arrhythmogenic right ventricular cardiomyopathy (dysplasia)	I
8. Restrictive cardiomyopathy	II
9. Siderotic cardiomyopathy (in particular thalassemia)	I
10. Non compaction	II
11. Post-cardiac transplantation rejection	Inv

Left ventricular hypertrophy

LV hypertrophy is an important independent risk factor for cardiac events. CMR is the best technique for assessing LV mass,[147,286] and following its progression over time (both for research trials[287–290] and for clinical patients), because of excellent interstudy reproducibility.[53,149,163]

Left ventricular non-compaction

This condition has become more recognised,[291] and appears to have autosomal dominant inheritance.[292] There is a failure of normal embryonic development of the myocardium from loosely arranged muscle fibres to the mature compacted form of myocardium. This has been linked with microvascular dysfunction,[293] and ventricular arrhythmias.[291] Variant forms seem to include left ventricular trabeculation which appears as a fine network or is more bizarre. CMR appears ideal for identification of this condition,[294] but there are no large comparison studies with echocardiography.

Dilated cardiomyopathy

The morphological and functional abnormalities of dilated cardiomyopathy (DCM) are clearly demonstrated and quantified by CMR. These findings may not distinguish DCM from other forms of LV dysfunction, such as that resulting from CAD. An advantage of CMR over echocardiography is the use of late gadolinium enhancement CMR, which shows no uptake in a majority of DCM patients. This confirms the diagnosis and precludes the need for invasive coronary angiography.[295] In some DCM patients, late gadolinium enhancement is seen, but only in the mid-myocardium in a non-coronary pattern which is clearly distinguishable from CAD, and is recognized by pathologists as mid-wall fibrosis seen at post-mortem. Another advantage of CMR is the superior depiction of dilation of the RV which is typical of DCM.[296] The quantitative effects of therapy can also be assessed by CMR.[297–299]

Arrhythmogenic right ventricular cardiomyopathy

CMR is an ideal technique to depict the structural and functional abnormalities of the RV and a substantial clinical role for CMR in the investigation of arrhythmogenic right ventricular cardiomyopathy (ARVC) has developed.[300,301] The diagnostic criteria of ARVC,[302] which CMR can show in the RV include regional wall motion abnormalities, increased RV volumes with quantification, morphological abnormalities (aneurysms, trabecular disarray) and increased myocardial signal suggesting fatty infiltration. Early work suggests that abnormal CMR find-

ings predict an adverse outcome in ARVC.[303] Experience in interpretation of CMR is required however, because of the normal variants of the RV which are in general greater than for the LV. Therefore isolated findings must be interpreted with caution. Focal wall motion abnormalities, especially focal dyskinesia, is generally felt to be a more reliable indicator of ARVC than intramyocardial fat. Overall, in centres with good experience however, CMR is a first line technique for investigating ARVC and following any progression in RV volumes, structure and function over time.

Siderotic cardiomyopathy

An often overlooked cause of heart failure which is important worldwide, is iron overload cardiomyopathy arising in patients with haemochromatosis or the inherited severe anaemias which require regular blood transfusions from birth. The most important of these conditions is beta-thalassemia major, with 60 000 affected children born annually.[304] Over 70% of these patients die from heart failure.[305] Repeated assessment of myocardial iron using biopsy is difficult because of safety issues, sampling error and patchy iron distribution. Recently, measurement of T2* using CMR has been shown to reflect tissue iron, and there is a clear relation between reduced myocardial T2* (<20 ms) indicating iron overload, and LV dysfunction.[306] Myocardial T2* increases in concert with LV function recovery in thalassemia patients with heart failure.[307] CMR has been used to evaluate different chelation regimes specifically for their action on the myocardium.[308] The CMR sequence can be completed quickly in a single breath-hold,[309] and has good reproducibility.[306]

Restrictive cardiomyopathy

CMR may be useful to depict the anatomic and functional abnormalities associated with infiltrative/restrictive cardiomyopathy.[310] Amyloid heart disease can be recognised by its typical alterations of diastolic function and morphology, including thickening of the interatrial septum.[311] Another contribution of CMR is the of visualisation of the pericardial thickness with spin echo CMR which aids in the differentiation from constriction.[312] Computed tomography may have similar accuracy in making this distinction.

Cardiac sarcoidosis

Although cardiac involvement in sarcoidosis is relatively uncommon, sudden death may be its initial clinical presentation and early detection of such involvement is thus important. However, clinical information and standard imaging techniques suffer from low diagnostic accuracy.[313] There are reports of the value of CMR in this condition.[314,315] Gadolinium-enhanced CMR demonstrates increased signal in hearts affected by sarcoidosis,[316–318] which reduces with steroid treatment and is therefore a potential therapeutic marker.[316,318]

Myocarditis

The clinical diagnosis of myocarditis is difficult as symptoms are variable and often non-specific. Myocardial biopsy carries some risk and is limited by the patchy involvement of the muscle in the inflammatory process. CMR shows focal increases of myocardial signal on T2-weighted and early gadolinium enhancement CMR (1–2 min) in acute myocarditis,[319,320] and also with late enhancement.[321]

Heart transplantation

The two most common clinical problems in patients following heart transplantation are detection of episodes of acute rejection, and identification of accelerated coronary artery disease commonly considered as chronic rejection. Acute rejection can be identified as an increase in myocardial mass,[322] areas of high myocardial signal intensity,[323] and an increase in T2 values.[324] These findings correlate with myocardial oedema or infiltration by mononuclear cells. However, these changes, as well as reductions in LV wall thickening, are not reliable indicators of acute rejection, particularly not in the early stages. CMR may help detect CAD associated with cardiac transplantation,[325] complications such as pericardial disease or intracavitary masses,[322] and the beneficial effects of medical treatment,[326] on the remodelling process associated with long term use of cyclosporin.[327]

Pericardial disease

Both CMR and CT are well suited to define anatomic abnormalities of the pericardium including pericardial thickening and effusions. CMR has the advantage of being able to depict and quantify the functional abnormalities which may be associated with pericardial disease.[328] The large field of view of CT and CMR is helpful in providing a better overview of the extent of pericardial disease, and to define the relationship with surrounding anatomic structures. For suspected pericardial thickening, CMR and CT are primary imaging modalities, with CT having an advantage for identification of pericardial calcium.

Pericardial effusions

Gradient echo and SSFP cine CMR generally show pericardial effusions with high signal intensity.[85] CMR may be of diagnostic value in patients with loculated or complex configurations of pericardial effusions.

Constrictive pericarditis

The characteristic anatomic and functional changes associated with constrictive pericardial disease (elongated and narrow RV, abnormal motion of the sigmoid shaped interventricular septum, enlargement of the right atrium and inferior caval vein, stagnant blood in the atria, and

pericardial thickening) are clearly identified with spin echo CMR.[329,330]

Pericardial thickening is the hallmark of pericardial constriction although cases of constriction without pericardial thickening detectable by imaging techniques have been described.[329] Both spin echo CMR and CT are superior to echocardiography in measuring pericardial thickness but CMR has the additional advantage of permitting assessment of haemodynamic impairment. However, in patients with severe heart failure and in those with poorly controlled atrial fibrillation, CT may be preferable to CMR because imaging time is shorter and ECG gating is not required. The reliability of CMR in making a diagnosis of pericardial constriction is indicated by its high positive predictive accuracy.[329]

Velocity mapping of flow may be helpful to assess functional sequelae of pericardial disease.[331] Flow mapping may be performed at the level of cardiac inflow through the superior or inferior vena cava, where a normal biphasic flow pattern may be demonstrated. In patients with constrictive physiology and abnormal cardiac filling, the second peak of caval flow may be attenuated.

Congenital abnormalities of the pericardium

Pericardial cysts can be identified and distinguished from other tumours based on their characteristic signal intensity on spin echo images, which is low on T1-weighted but high on T2-weighted images. Signal is usually high on gradient echo cines. However, differential diagnosis from a necrotic or cystic mediastinal tumour, especially if it is situated in the typical location for a pericardial cyst, the right costophrenic angle, may be difficult. Absence of the pericardium is indicated by a leftward shift of the long axis of the heart visible using CMR.[332] The protrusion of a portion of the heart, which is usually associated with partial absence of the left-sided pericardium is easily observed on spin echo images. However, due to the absence of epicardial and epipericardial fat over the left ventricle, the pericardial defect itself may not be seen on spin echo images.[333]

Cardiac tumours

Transthoracic echocardiography is the usual technique which detects intracardiac tumours. However, in many cases the characterization is incomplete, and CMR is particularly helpful in determining the relationship to normal intracardiac structures and tumour extension to adjacent vascular and mediastinal structures,[334] infiltration into the pericardium,[335] and surgical planning.[336] In addition to this, there are a number of CMR features which can assist in tumour characterization.[337,338] The signal intensity of a lesion is dependent on the interaction of the tissue composition and the CMR parameters employed for imaging. The differential diagnosis of a high signal intensity lesion on T1-weighted images includes fatty tumours (lipoma, liposarcoma), recent haemorrhage (due to methaemoglobin breakdown products), some cystic lesions (due to the high protein content of the contents of the cyst), and melanoma (due to the effects of melanin). A lesion with low signal intensity on T1-weighted images may represent a cyst filled with low protein fluid, a signal void in a vascular malformation, a calcified lesion or the presence of air. Cysts typically have high signal intensity on T2-weighted independent of the protein concentration of the fluid. Fat saturation can be used to diagnose fatty content definitively. Further differentiation of the tumour can be made with gadolinium. During the first pass, vascular tumours (haemangioma, angiosarcoma) show early enhancement and small vessels may be easily identifiable. In the early phase, after injection at 1–2 min, necrotic areas in malignant tumours show as dark areas surrounded by enhancement elsewhere. In the later phase, malignant tumours typically show contrast enhancement indicating tissue vascularity. Such enhancement is usually absent in cystic lesions, and most benign tumours (haemangiomas and myxomas being exceptions). Thrombus in the ventricles is well shown by modern CMR sequences, including SSFP cines, and late gadolinium enhancement,[270] and for this application may be more sensitive than echocardiography.

Valvular heart disease

The low cost, flexibility and ease of handling make transthoracic echocardiography the primary clinical tool for evaluation of valvular heart disease. Moreover, TEE is superior to CMR in assessment of valve morphology and detection of small and rapidly moving vegetations attached to the valves in endocarditis. However, CMR may play a complementary role when transthoracic acoustic windows are poor and a TEE approach is undesirable, or when results of echocardiography and catheterization are conflicting. Furthermore, CMR is a valuable tool for individual follow-up of the severity of regurgitant lesions and for quantification of the effects of valvular lesions on ventricular volumes, function and myocardial mass (see Table 5).

Technical aspects

As normal heart valves are thin and rapidly moving, visualization on conventional spin-echo images may be difficult but breath-hold spin-echo techniques allow complete visualization of normal aortic valve leaflets in 85% of patients.[339] Abnormal valves are more easily seen because they are thicker and may be less mobile. Calcifications give rise to loss of signal and may lead to underestimation of valve pathology on spin-echo images. Generally, gradient echo cines are more informative as myocardial and valvular function are dynamically displayed. A phenomenon characteristic of older gradient-echo cine CMR is referred to as intravoxel dephasing

Table 5 Indications for CMR in patients with valvular heart disease

Indication	Class
1. Valve morphology	
Bicuspid aortic valve	II
Other valves	III
Vegetations	Inv
2. Cardiac chamber anatomy and function	I
3. Quantification of regurgitation	I
4. Quantification of stenosis	III
5. Detection of paravalvular abscess	Inv
6. Assessment of prosthetic valves	Inv

which leads to signal loss demonstrating turbulence found in heart valve lesions. This signal-loss can be seen in the proximity of rapidly moving valves or at sites of stenoses where flow is accelerated and turbulent. Jets of signal-loss indicate valvular stenosis or incompetence. Whilst the length and area of the signal-loss jet help to indicate the severity of the valvular defect, they are only semi-quantitative,[340] because the extent of the jet depends on the combination of haemodynamic variables such as size and shape of the valve orifice, the pressure gradient, and technical parameters of the pulse sequence.[341] Modern CMR systems with high gradient performance typically acquire cines using the SSFP technique, which is less dependent on the inflow of magnetically non-saturated blood within the imaging slice. This makes the blood appear brighter, and it is less sensitive to intravoxel dephasing thereby reducing the jet of signal loss.

Velocity mapping CMR is a well validated approach to quantify blood flow velocity in large vessels, and is useful to quantify the severity of regurgitant and stenotic valve lesions. The direction of velocity is generally obtained through-plane with the imaging plane perpendicular to the direction of flow. Integration of velocities over the cross-section of a vessel yields flow rate (mL/s) when multiplied by the vessel cross-sectional area. By integration over the entire cardiac cycle, the stroke volume is obtained. New technical developments include adaptation of the imaging slice to motion of the valve annulus with simultaneous correction of the velocity measurements to through-plane motion of the heart, and real-time colour flow CMR.[342,343]

Regurgitation

Valvular regurgitation is identified by means of the jet of signal loss on cine gradient echo CMR, but the size of the jet is highly sequence-dependent. A quantitative assessment of single valve lesions can be obtained by calculating the regurgitant volume from the difference of RV and LV stroke volume.[344,345] If single valves on both sides of the heart are regurgitant, the method can be extended to determine regurgitant volume from the subtraction of the ventricular stroke volume from the great vessel flow on the same side. Regurgitant fraction is calculated as the regurgitant volume divided by the ventricular stroke volume.

Aortic regurgitation may be associated with a semicircular shaped signal void proximal to the leaking orifice during diastole.[346] Using velocity mapping CMR, the aortic regurgitant volume and fraction can be obtained directly by measuring the retrograde volume flow in diastole in the ascending aorta.[84] This simple and direct approach is more quantitative than Doppler, and has been used to identify patients responsive to angiotensin-converting enzyme inhibitor therapy,[347] and hydralazine.[348] It has high interstudy reproducibility, which is valuable for repeated estimations.[349] The flow acquisition should be placed between the aortic valve and the coronary ostia to avoid inaccuracies from aortic compliance and coronary flow.[350]

Mitral regurgitation may be central or eccentric,[351,352] and can be quantified by comparing total LV stroke volume derived from short axis multi-slice volumetry with the net forward stroke volume obtained with velocity mapping CMR in the ascending aorta. This method compares favourably with catheterization and Doppler echocardiography.[353,354] More direct methods for measuring systolic regurgitant flow and ventricular inflow at the mitral annulus level are complicated by through-plane motion of the annulus and by eccentricity of the regurgitant jet.[355] Methods to correct for inaccuracies have been developed but are currently not routinely available.[356,357]

Stenosis

Bicuspid or fused aortic valves can be identified with accurate positioning of the imaging plane in early systole perpendicular to the doming valve leaflets. Direct planimetry of the orifice area is also feasible.[358] Calcification of the leaflet tips may be difficult to differentiate from signal loss due to turbulence and may thus lead to overestimation of the valve opening area, however, calcifications are usually located within the cusps and interference with measurements of valve area is uncommon. Non-uniform and accelerated flow distal to an abnormal valve causes signal loss in cine gradient echo cine CMR and may indicate valve stenosis. The extent of the jet cannot be used as an accurate measure of stenosis severity because of its dependency on settings of CMR parameters. For example, a short TE reduces the magnitude of the signal void. Using velocity mapping CMR, the peak velocity within the core of the jet can be measured in alignment with the jet direction or perpendicular to it, and the modified Bernouilli equation used to estimate the pressure gradient. Short TE sequences are required to avoid loss of velocity information in areas of turbulent flow. Close agreement has been demonstrated between CMR, catheterisation and Doppler echocardiography in patients with mitral and aortic valve stenosis.[359,360] As valve area measurements by cardiac catheterization may be complicated by occult strokes,[361] CMR could be used to quantify the valve area in aortic stenosis[362] when echocardiography is not

possible or non-concordant data with invasive techniques have been obtained.

Prosthetic valves

CMR is safe in patients with prosthetic heart valves at 1.5 Tesla, as the heart valve prostheses have no substantial interactions with the magnetic field and heating is negligible.[363] However, they do produce focal artefacts and signal loss due to distortion of the magnetic field by the metal contained within the prostheses. The artefacts are least pronounced on spin-echo images and more pronounced with gradient-echo cines. As a consequence, smaller jets of signal loss due to paravalvular leakage may be obscured by the artefact. Heart motion-adapted velocity mapping has allowed the measurement of velocity profiles close to aortic valve prostheses.[364]

Cardiovascular magnetic resonance spectroscopy

CMR spectroscopy for clinical purposes is presently limited to the study of P-31 containing myocardial phosphates present in important biochemical compounds involved in energy metabolism. Compounds such as adenosine triphosphate (ATP), phosphocreatinine (PCr), inorganic phosphate (Pi) and monophosphate esters (MPE) can be studied at rest and during stress. Although other important elements can be studied by CMR spectroscopy, none are currently used clinically. Nevertheless, potentially clinically relevant results have been reported with in vivo human studies of hydrogen (H-1),[365,366] sodium (Na-23),[367] and potassium (K-39).[368] The main reason for their limited clinical application is the low MR sensitivity of other nuclei and their low concentration, which results in a very low signal. At present, CMR spectroscopy can only interrogate anterior portions of the heart, but higher field strength magnets and new coils should improve the coverage.

A primary clinical goal of CMR spectroscopy is to determine the PCr/ATP ratio, which reflects the energetic state of the myocardium. Important conceptual studies suggest that the unique ability to interrogate the high energy pathway has significant diagnostic and prognostic potential. In mild heart failure, the PCr/ATP ratio is in the normal range,[369,370] but falls with advancing severity.[369,371] Reduced PCr/ATP ratios improve with treatment of heart failure,[369] and the level of PCr/ATP is an independent predictor of cardiovascular events which may be more predictive than ejection fraction.[372] In patients with valvular disease, PCr/ATP ratios are reduced only when patients develop heart failure but not in early stages.[373] Whether PCr/ATP ratios can be used clinically to guide the timing for valve replacement is currently unknown. In CAD, myocardial ischemia induced during handgrip exercise can be detected by transient reduction in the PCr/ATP ratio. This response is abolished by revascularization.[374] This ischaemic response is not seen in non-viable regions.[375] Viable myocardium has been shown to have normal absolute levels of ATP, but levels are low in non-viable myocardium.[376] Stunned myocardium has been shown to have normal PCr/ATP ratios.[377] Taken together, these results suggest that CMR spectroscopy can provide metabolic evidence for myocardial viability.[365] In early cardiac allograft rejection, decreased PCr/ATP ratios are seen,[378,379] although this must be distinguished from transient reductions early after transplantation that might occur on the basis of transient allograft ischaemia. In LV hypertrophy, the PCr/ATP ratio is generally normal,[380] but reductions are seen in hypertrophic cardiomyopathy.[381,382] The reasons for this are not currently understood. Finally, a decrease in PCr/ATP ratio has been found in 20% of women with chest pain in the absence of significant epicardial coronary artery stenosis, a result which suggests the presence of microvascular disease and resultant ischaemia.[383]

Costs and benefits of CMR

This section focuses on the USA and UK where cost data and technology assessments of CMR have been undertaken; the principles apply however to most European Union (EU) countries and elsewhere.[384,385] There are a number of medical society and governmental position papers on the economic value of CMR and other imaging techniques, and these are a useful further reference source for independent assessments of cost-benefit.[384–396] A large amount of data reveals that there is a large economic burden placed upon society for the use of imaging tests for cardiovascular disease. For example, high rates of resource consumption are noted in the US (~40 million non-invasive cardiac tests are performed annually for public and private health care payers; Medicare reimbursement of $372–$740 million; and high growth rates >20% using Medicare databases for some cardiac imaging modalities). The same applies in most countries of the EU, but in some there is underutilization of procedures.[397] In this latter case, the opportunity exists that societal investment in more accurate and diverse technology may supplant the use of inexpensive and less accurate diagnostic testing modalities. This might be feasible in the more urban or centralized health care environments.

Current efforts to contain health care costs in the US and Europe have included developing evidence-based guidelines where a threshold body of clinical and economic evidence is desired to support and guide reimbursement for a given clinical procedure indication. Despite the concern over excessive and rising costs of care, the current armamentarium for cardiac imaging has suffered from technical artefacts, limited resolution, and other challenges that often provide a unidimensional risk evaluation upon which patient management is based. Thus, the promise to society for CMR is to develop strategies that provide a full range of risk markers which would allow health care systems to benefit from improved diagnostic accuracy, risk assessment and thera-

peutic decision making. The resultant economic effects of these improvements may result in decreases in overall test use, early diagnosis, improved patient outcome, decreased hospitalizations and length of stay, and reduced invasive procedure use. As many countries currently track cardiovascular mortality rates, the impact of early diagnosis on long-term survival may provide a link to shifting health care resources and the decision to utilize differential technology in order to exhibit a more beneficial impact on population-based risk reduction efforts.

Cost implications of functional CMR

CMR permits accurate and precise measurements of cardiac chamber sizes and volumes, rendering it ideal to detail abnormalities in complex diseases. A hierarchical testing approach in which lower cost tests are applied to a greater percentage of patients and higher cost tests are limited to high-risk patients where a greater incremental value is determined,[398] is based upon high-risk cost effectiveness model in which economic value is greater in higher risk populations who receive a greater proportional benefit to testing and treatment (in the form of disproportionately greater risk reduction when compared to lower risk cohorts). By applying this principle of high-risk cost models, costs can be differentially and selectively allocated to sicker patients and thereby result in more cost efficient care shifting higher risk patients from ultrasound or nuclear-based techniques to CMR. Additionally, the upfront cost differences are minimised by the greater outcome benefit to that patient cohort, rendering the test more cost effective.

Cost implications of CMR perfusion and viability testing

CMR has the potential to provide myocardial perfusion measures. Evidence in small patient samples reveals a sensitivity and specificity of 87% and 85%, respectively, versus catheterization as the gold standard,[202] and improved detection of infarction versus SPECT.[248] A considerable amount of diagnostic and prognostic data are available with SPECT however and despite a substantial radiation burden of SPECT, it appears that perfusion CMR may take time to become competitive due to the current favourable reimbursement for perfusion SPECT, with function as an add-on.[399] The detection of subendocardial ischaemia by CMR techniques could prove to be clinically and cost effective for large segments of the SPECT population (for example women evaluated for chest pain symptoms).[215]

Despite this initial caution on the use of perfusion, viability testing with CMR may become the gold standard for the assessment of patients with LV dysfunction presenting for evaluation and consideration of coronary revascularization. Using a model of high risk cost-effectiveness, evidence of CMR viability would result in improved patient outcome with coronary revascularization and reduced cost (due to reduced hospitalisations for heart failure, acute myocardial infarction, etc.). The incremental cost effectiveness ratio of viability testing with CMR when compared with echocardiography, SPECT, or PET techniques could result in a dominant economic strategy of improved life years saved and cost savings.

Cost implications of coronary CMR

Currently, 1.2 million diagnostic coronary X-ray angiograms are performed annually in the USA which carries a small risk due to the invasive procedure, the contrast media, and the radiation exposure. Although under development, coronary MRA provides an opportunity to reduce these risks. If coronary MRA could be utilized to screen lower risk patients currently referred for catheterization, substantial cost savings may be achieved amongst the patients with normal catheterization (current rate in USA approximately 35%). In one report, the total cost savings, when compared to diagnostic coronary angiography, was expected to exceed $1000 per patient (or >60% cost reduction).[399]

In the area of carotid and peripheral MRA, there are existing cost effectiveness analysis that may be used to guide the utilization of these techniques. In a recent review by the UK's National Institute of Clinical Excellence (NICE), the high sensitivity (93%) and specificity (94%) in the detection of carotid disease, resulting in cost-effectiveness ratios of £19 419 (approximately €27 000) per quality adjusted life years saved.[384] Thus, in the evaluation of carotid disease, MRA was the cost-effective test of choice. A cost-effectiveness analysis was also performed by NICE in the evaluation of peripheral arterial disease comparing MRA (94% sensitivity and 93% specificity) with X-ray angiography. There was little difference in 1 year outcomes, a small complication risk with the invasive angiography and reduced costs with MRA. Thus, MRA was considered the favourable choice, except for the highest risk patients who should be referred to X-ray angiography.

Cost implications for the pharmaceutical industry

It costs an estimated $500 million to bring a new drug to the marketplace. Although the majority of drug development costs are in preclinical research, the average cost of FDA-sponsored Phase I to IIIb clinical trials ranges from $14 to $54 million. There is increasing interest on the part of pharmaceutical manufacturers to reduce the frequency with which large morbidity and mortality outcome trials are utilized by re-focusing resources early on in drug development to areas of distinct clinical promise. An alternative to the use of large outcome trials is to use an imaging or laboratory marker as a surrogate outcome. A surrogate outcome is, by definition, a process of care measure that may be used to reflect a worsening long-term outcome (e.g., worsening ejection fraction). Due to the enhanced reproducibility of CMR measurements,[53] it appears ideally suited for use as a surrogate outcome. Prior research supports the view that CMR

can reduce the necessary and sufficient sample sizes by as much as 10-fold and decrease overall cost by as much as 80%.[149,163] Using simple cost calculations, approximately 5–11% of drug development costs may be saved thus providing substantial reductions in costs to society.

Comparative test costs

The current estimated costs of cardiac imaging modalities are shown in Table 6. As a number of CMR techniques are currently under development, these cost estimates should be viewed with caution. Despite this, the estimated unit procedural cost (not charge) of CMR ranges from €194 to €1063 based upon multiple sources.[384,385,399] Current estimates of CMR costs are expected to decline over the next decade as training costs, initial protocol development, and equipment costs contribute to higher initial development costs for this modality. An example of lower achieved costs can be seen in the area of more mature CMR techniques, such as can be seen with peripheral MRA techniques.[384] As is noted with vascular MRA costs, in the UK the unit cost for some MR procedures has been estimated at £110 and £247 for evaluation of carotid arteries and peripheral vasculature.[384] Upon reviewing the initial cost estimates, it appears that CMR is quite cost competitive when compared to other modalities. One would anticipate with continued use and protocol refinement, enhanced efficiency and cost reductions for CMR will ensue.

Test use is guided by both economic forces, such as reimbursement, and information content. For CMR, the multitudes of test parameters that can be acquired render this test unlike other non-invasive imaging modalities. Its ability to acquire diverse risk markers may, in some cases, raise the overall procedural cost but its upfront cost may be minimized by substantial downstream cost savings. Economic value may be achieved by developing a single, non-invasive test that assesses all aspects of the heart, and CMR has the potential to provide this comprehensive examination in one sitting at considerably less risk and cost to the patient. With rapid imaging techniques, it should be possible to complete a comprehensive study in as little as one hour, at an estimated median cost of €435. The effect of this initial test cost may be offset by a reduction in downstream utilization of other redundant imaging tests. Using a rudimentary cost analysis, adding the ability of CMR to perform multiple test functions may therefore provide cost savings to the health care system.

Table 6 Estimated average costs of CMR and other common cardiac imaging procedures when compared to 2D echocardiography

	Average Cost	Cost range
Echocardiography	[a]	[a]
Computed Tomography	3.13	(±1.39)
SPECT	3.27	(±2.88)
CMR	5.51	(±3.51)
PET	14.03	(±9.62)
Right and Left Heart Catheterization	19.96	(±13.55)

[a] Echocardiography is the cost comparator where costs of other modalities are a ratio of *x*-fold higher costs. Note: Costs are unit operating costs (not charges) derived from multiple sources.[384,385,399] CMR cost does not include the cost of intravenous contrast agents or stress protocols. Conversion of US Costs to Euros based upon CPT codes: 75552, 75553, 75554, 75555 (based upon average for Atlanta, Georgia, US, August 19, 2003).

References

1. Sechtem UP, Neubauer S, Revel D et al. Report of the Task Force of the European Society of Cardiology, in collaboration with the European Association of Radiology and the Association of European Pediatric Cardiologists: clinical indications of magnetic resonance techniques in cardiovascular disease. *Eur Heart J* 1998;**19**:19–39.
2. Manning WJ, Pennell DJ. Cardiovascular magnetic resonance. Churchill Livingstone: Philadelphia, USA. ISBN 0-443-07519-0, 2002.
3. Higgins CB, de Roos A. Cardiovascular MRA and MRI. Lippincott Williams & Wilkins; 2003.
4. Francis JM, Pennell DJ. The treatment of claustrophobia during cardiovascular magnetic resonance; use and effectiveness of mild sedation. *J Cardiovasc Magn Reson* 2000;**2**:139–41.
5. Martin ET, Coman JA, Shellock FG et al. Magnetic resonance imaging and cardiac pacemaker safety at 1.5-Tesla. *J Am Coll Cardiol* 2004;**43**:1315–24.
6. Hirsch R, Kilner PJ, Connelly MS et al. Diagnosis in adolescents and adults with congenital heart disease. Prospective assessment of individual and combined roles of magnetic resonance imaging and transesophageal echocardiography. *Circulation* 1994;**90**:2937–51.
7. Hoppe U, Dederichs B, Deutsch HJ et al. Congenital heart disease in adults and adolescents: comparative value of transthoracic and transesophageal echocardiography and MR imaging. *Radiology* 1996;**199**:669–77.
8. Geva T, Vick GW, Wendt RE et al. Role of spin echo and cine magnetic resonance imaging in presurgical planning of heterotaxy syndrome. Comparison with echocardiography and catheterization. *Circulation* 1994;**90**:348–56.
9. Razavi R, Hill DL, Keevil SF et al. Cardiac catheterisation guided by MRI in children and adults with congenital heart disease. *Lancet* 2003;**362**:1877–82.
10. Pohost GM, Higgins CB, Grist TM et al. Guidelines for credentialing in CMR (Cardiovascular Magnetic Resonance). Society of Cardiovascular Magnetic Resonance (SCMR) Clinical Practice Committee. *J Cardiovasc Magn Reson* 2000;**2**:233–4.
11. Kersting-Sommerhoff BA, Diethelm L, Stanger P et al. Evaluation of complex congenital ventricular anomalies with magnetic resonance imaging. *Am Heart J* 1990;**120**:133–42.
12. Hundley WG, Li HF, Lange RA et al. Assessment of left-to-right intracardiac shunting by velocity-encoded, phase-difference magnetic resonance imaging. A comparison with oximetric and indicator dilution techniques. *Circulation* 1995;**91**:2955–60.
13. Taylor AM, Stables RH, Poole-Wilson PA et al. Definitive clinical assessment of atrial septal defect by magnetic resonance imaging. *J Cardiovasc Magn Reson* 1999;**1**:43–7.
14. Greil GF, Powell AJ, Gildein HP et al. Gadolinium-enhanced three-dimensional magnetic resonance angiography of pulmonary and systemic venous anomalies. *J Am Coll Cardiol* 2002;**39**:335–41.
15. Valsangiacomo ER, Levasseur S, McCrindle BW et al. Contrast-enhanced MR angiography of pulmonary venous abnormalities in children. *Pediatr Radiol* 2003;**33**:92–8.
16. Prasad SK, Soukias N, Hornung T et al. Role of magnetic resonance angiography in the diagnosis of major aortopulmonary collateral arteries and partial anomalous pulmonary venous drainage. *Circulation* 2004;**109**:207–14.
17. White CS, Baffa JM, Haney PJ et al. MR imaging of congenital anomalies of the thoracic veins. *Radiographics* 1997;**17**:595–608.
18. Dill T, Neumann T, Ekinci O et al. Pulmonary vein diameter reduction after radiofrequency catheter ablation for paroxysmal atrial fibrillation evaluated by contrast-enhanced three-dimensional magnetic resonance imaging. *Circulation* 2003;**107**:845–50.

19. Chung KJ, Simpson IA, Glass RF et al. Cine magnetic resonance imaging after surgical repair in patients with transposition of the great arteries. *Circulation* 1988;**77**:104–9.
20. Kersting-Sommerhoff B, Diethelm L, Teitel DF et al. Magnetic resonance imaging of congenital heart disease: sensitivity and specificity using receiver operating characteristic curve analysis. *Am Heart J* 1989;**118**:155–61.
21. Araoz PA, Reddy GP, Thomson PD et al. Images in cardiovascular medicine. Magnetic resonance angiography of criss-cross heart. *Circulation* 2002;**105**:537–8.
22. Yoo SJ, Kim YM, Choe YH. Magnetic resonance imaging of complex congenital heart disease. *Int J Card Imaging* 1999;**15**:151–60.
23. Didier D, Higgins CB. Identification and localization of ventricular septal defect by gated magnetic resonance imaging. *Am J Cardiol* 1986;**57**:1363–8.
24. Mirowitz SA, Gutierrez FR, Canter CE et al. Tetralogy of Fallot: MR findings. *Radiology* 1989;**171**:207–12.
25. Sechtem U, Pflugfelder P, Cassidy MC et al. Ventricular septal defect: visualization of shunt flow and determination of shunt size by cine MR imaging. *Am J Roentgenol* 1987;**149**:689–92.
26. Kersting-Sommerhoff B, Seelos KC, Hardy C et al. Evaluation of surgical procedures for cyanotic congenital heart disease by using MR imaging. *Am J Roentgenol* 1990;**155**:259–66.
27. Mayo JR, Roberson D, Sommerhoff B et al. MR imaging of double outlet right ventricle. *J Comput Assist Tomogr* 1990;**14**:336–9.
28. Rebergen SA, Chin JG, Ottenkamp J et al. Pulmonary regurgitation in the late postoperative follow-up of tetralogy of Fallot. Volumetric quantitation by nuclear magnetic resonance velocity mapping. *Circulation* 1993;**92**:1123–32.
29. Holmqvist C, Oskarsson G, Stahlberg F et al. Functional evaluation of extracardiac ventriculopulmonary conduits and of the right ventricle with magnetic resonance imaging and velocity mapping. *Am J Cardiol* 1999;**83**:926–32.
30. Link KM, Herrera MA, D'Souza VJ et al. MR imaging of Ebstein anomaly: results in four cases. *Am J Roentgenol* 1988;**150**:363–7.
31. Choi YH, Park JH, Choe YH et al. MR imaging of Ebstein's anomaly of the tricuspid valve. *Am J Roentgenol* 1994;**163**:539–43.
32. Mohiaddin RH, Kilner PJ, Rees S et al. Magnetic resonance volume flow and jet velocity mapping in aortic coarctation. *J Am Coll Cardiol* 1993;**22**:1515–21.
33. Steffens JC, Bourne MW, Sakuma H et al. Quantification of collateral blood flow in coarctation of the aorta by velocity encoded cine magnetic resonance imaging. *Circulation* 1994;**90**:937–43.
34. Rees S, Somerville J, Ward C et al. Coarctation of the aorta: MR imaging in late postoperative assessment. *Radiology* 1989;**173**: 499–502.
35. Simpson IA, Chung KJ, Glass RF et al. Cine magnetic resonance imaging for evaluation of anatomy and flow relations in infants and children with coarctation of the aorta. *Circulation* 1988;**78**: 142–8.
36. Bogaert J, Kuzo R, Dymarkowski S et al. Follow-up of patients with previous treatment for coarctation of the thoracic aorta: comparison between contrast-enhanced MR angiography and fast spin-echo MR imaging. *Eur Radiol* 2000;**10**:1847–54.
37. Kersting-Sommerhoff BA, Sechtem UP, Fisher MR et al. MR imaging of congenital anomalies of the aortic arch. *Am J Roentgenol* 1987;**149**:9–13.
38. Jaffe RB. Magnetic resonance imaging of vascular rings. *Semin Ultrasound CT MR* 1990;**11**:206–20.
39. Bijl M, Bronzwaer JG, van Rossum AC et al. Angina pectoris due to left main coronary artery compression in Eisenmenger ductus arteriosus. *Am Heart J* 1993;**125**:1767–71.
40. Kersting-Sommerhof BA, Sechtem UP, Higgins CB. Evaluation of pulmonary blood supply by nuclear magnetic resonance imaging in patients with pulmonary atresia. *J Am Coll Cardiol* 1988;**11**:166–71.
41. Vick GW, Rokey R, Huhta JC et al. Nuclear magnetic resonance imaging of the pulmonary arteries, subpulmonary region, and aorticopulmonary shunts: a comparative study with two-dimensional echocardiography and angiography. *Am Heart J* 1990;**119**:1103–10.
42. Julsrud PR, Ehmann RL, Hagler DJ et al. Extracardiac vasculature in candidate for Fontan surgery: MR imaging. *Radiology* 1989;**173**:503–6.
43. Gomes AS, Lois JF, Williams RG. Pulmonary arteries: MR imaging in patients with congenital obstruction of the right ventricular outflow tract. *Radiology* 1990;**174**:51–7.
44. Geva T, Greil GF, Marshall AC et al. Gadolinium-enhanced 3-dimensional magnetic resonance angiography of pulmonary blood supply in patients with complex pulmonary stenosis or atresia: comparison with X-ray angiography. *Circulation* 2002;**106**:473–8.
45. Rebergen SA, Ottenkamp J, Doornbos J et al. Postoperative pulmonary flow dynamics after Fontan surgery: assessment with nuclear magnetic resonance velocity mapping. *J Am Coll Cardiol* 1993;**21**:123–31.
46. Greenberg SB, Crisci KL, Koenig P et al. Magnetic resonance imaging compared with echocardiography in the evaluation of pulmonary artery abnormalities in children with tetralogy of Fallot following palliative and corrective surgery. *Pediatr Radiol* 1997;**27**:932–5.
47. Kondo C, Takada K, Yokoyama U et al. Comparison of three-dimensional contrast-enhanced magnetic resonance angiography and axial radiographic angiography for diagnosing congenital stenoses in small pulmonary arteries. *Am J Cardiol* 2001;**87**:420–4.
48. Gomes AS, Lois JF, Williams RG. Pulmonary arteries: MR imaging in patients with congenital obstruction of the right ventricular outflow tract. *Radiology* 1990;**174**:51–7.
49. Jacobstein MD, Fletcher BD, Nelson AD et al. Magnetic resonance imaging: evaluation of palliative systemic-pulmonary artery shunts. *Circulation* 1984;**70**:650–6.
50. Canter CE, Gutierrez FR, Mirowitz SA et al. Evaluation of pulmonary arterial morphology in cyanotic congenital heart disease by magnetic resonance imaging. *Am Heart J* 1989;**118**:347–54.
51. Canter CE, Gutierrez FR, Molina P et al. Noninvasive diagnosis of right-sided extracardiac conduit obstruction by combined magnetic resonance imaging and continuous-wave Doppler echocardiography. *J Thorac Cardiovasc Surg* 1991;**101**:724–31.
52. Martinez JE, Mohiaddin RH, Kilner PJ et al. Obstruction in extracardiac ventriculopulmonary conduits: value of nuclear magnetic resonance imaging with velocity mapping and Doppler echocardiography. *J Am Coll Cardiol* 1992;**20**:338–44.
53. Grothues F, Smith GC, Moon JC et al. Comparison of interstudy reproducibility of cardiovascular magnetic resonance with two-dimensional echocardiography in normal subjects and in patients with heart failure or left ventricular hypertrophy. *Am J Cardiol* 2002;**90**:29–34.
54. Helbing WA, Bosch HG, Maliepaard C et al. Comparison of echocardiographic methods with magnetic resonance imaging for assessment of right ventricular function in children. *Am J Cardiol* 1995;**76**:589–94.
55. Grothues F, Moon JC, Bellenger NG et al. Interstudy reproducibility of right ventricular volumes, function and mass with cardiovascular magnetic resonance. *Am Heart J* 2004;**147**:218–23.
56. Roest AA, Helbing WA, Kunz P et al. Exercise MR imaging in the assessment of pulmonary regurgitation and biventricular function in patients after tetralogy of Fallot repair. *Radiology* 2002;**223**:204–11.
57. Niezen RA, Helbing WA, van der Wall EE et al. Biventricular systolic function and mass studied with MR imaging in children with pulmonary regurgitation after repair for tetralogy of Fallot. *Radiology* 1996;**201**:135–40.
58. Helbing WA, Niezen RA, Le Cessie S et al. Right ventricular diastolic function in children with pulmonary regurgitation after repair of tetralogy of Fallot: volumetric evaluation by magnetic resonance velocity mapping. *J Am Coll Cardiol* 1996;**28**:1827–35.
59. Kuehne T, Saeed M, Reddy G et al. Sequential magnetic resonance monitoring of pulmonary flow with endovascular stents placed across the pulmonary valve in growing Swine. *Circulation* 2001;**104**:2363–8.
60. Kondo C, Hardy C, Higgins SS et al. Nuclear magnetic resonance imaging of the palliative operation for hypoplastic left heart syndrome. *J Am Coll Cardiol* 1991;**18**:817–23.
61. Fogel MA, Weinberg PM, Chin AJ et al. Late ventricular geometry and performance changes of functional single ventricle throughout

staged Fontan reconstruction assessed by magnetic resonance imaging. *J Am Coll Cardiol* 1996;**28**:212–21.
62. Rees RSO, Firmin DN, Mohiaddin RH et al. Application of flow measurements by magnetic resonance velocity mapping to congenital heart disease. *Am J Cardiol* 1989;**64**:953–6.
63. Niwa K, Tashima K, Kawasoe Y et al. Magnetic resonance imaging of myocardial infarction in Kawasaki disease. *Am Heart J* 1990;**119**:1293–302.
64. Duerinckx AJ, Troutman B, Allada V et al. Coronary MR angiography in Kawasaki disease. *Am J Roentgenol* 1997;**168**:114–6.
65. Greil GF, Stuber M, Botnar RM et al. Coronary magnetic resonance angiography in adolescents and young adults with Kawasaki disease. *Circulation* 2002;**105**:908–11.
66. Taylor AM, Thorne SA, Rubens MB et al. Coronary artery imaging in grown-up congenital heart disease: Complementary role of MR and X-ray coronary angiography. *Circulation* 2000;**101**:1670–8.
67. Li J, Soukias ND, Carvalho JS et al. Coronary arterial anatomy in tetralogy of Fallot: morphological and clinical correlations. *Heart* 1998;**80**:174–83.
68. Felmeden D, Singh SP, Lip GY. Anomalous coronary arteries of aortic origin. *Int J Clin Pract* 2000;**54**:390–4.
69. Post JC, van Rossum AC, Bronzwaer JG et al. Magnetic resonance angiography of anomalous coronary arteries. A new gold standard for delineating the proximal course?. *Circulation* 1995;**92**:3163–71.
70. McConnell MV, Ganz P, Selwyn AP et al. Identification of anomalous coronary arteries and their anatomic course by magnetic resonance coronary angiography. *Circulation* 1995;**92**:3158–62.
71. Bunce NH, Lorenz CH, Keegan J et al. Coronary artery anomalies: assessment with free-breathing three-dimensional coronary MR angiography. *Radiology* 2003;**227**:201–8.
72. Lutz AM, Willmann JK, Pfammatter T et al. Evaluation of aortoiliac aneurysm before endovascular repair: comparison of contrast-enhanced magnetic resonance angiography with multidetector row computed tomographic angiography with an automated analysis software tool. *J Vasc Surg* 2003;**37**:619–27.
73. Castrucci M, Mellone R, Vanzulli A et al. Mural thrombi in abdominal aortic aneurysms: MR imaging characterization – useful before endovascular treatment. *Radiology* 1995;**197**:135–9.
74. Meaney JF, Prince MR, Nostrant TT et al. Gadolinium-enhanced MR angiography of visceral arteries in patients with suspected chronic mesenteric ischemia. *J Magn Reson Imaging* 1997;**7**:171–6.
75. Mosca RS, Kulik TJ, Marshall K et al. Mycotic pseudoaneurysm associated with aortic coarctation. *J Cardiovasc Magn Reson* 2000;**2**:209–12.
76. Akins EW, Slone RM, Wiechmann BN et al. Perivalvular pseudoaneurysm complicating bacterial endocarditis: MR detection in five cases. *AJR Am J Roentgenol* 1991;**156**:1155–8.
77. Engellau L, Larsson EM, Albrechtsson U et al. Magnetic resonance imaging and MR angiography of endoluminally treated abdominal aortic aneurysms. *Eur J Vasc Endovasc Surg* 1998;**15**:212–9.
78. Anbarasu A, Harris PL, McWilliams RG. The role of gadolinium-enhanced MR imaging in the preoperative evaluation of inflammatory abdominal aortic aneurysm. *Eur Radiol* 2002;**12**(Suppl.):S192–5.
79. Cejna M, Loewe C, Schoder M et al. MR angiography vs CT angiography in the follow-up of nitinol stent grafts in endoluminally treated aortic aneurysms. *Eur Radiol* 2002;**12**:2443–50.
80. Nienaber CA, von Kodolitsch Y, Nicolas V et al. The diagnosis of thoracic aortic dissection by noninvasive imaging procedures. *N Engl J Med* 1993;**328**:1–9.
81. Sommer T, Fehske W, Holzknecht N et al. Aortic dissection: a comparative study of diagnosis with spiral CT, multiplanar transesophageal echocardiography, and MR imaging. *Radiology* 1996;**199**:347–52.
82. Cesare ED, Giordano AV, Cerone G et al. Comparative evaluation of TEE, conventional MRI and contrast-enhanced 3D breath-hold MRA in the post-operative follow-up of dissecting aneurysms. *Int J Card Imaging* 2000;**16**:135–47.
83. Pereles FS, McCarthy RM, Baskaran V et al. Thoracic aortic dissection and aneurysm: evaluation with nonenhanced true FISP MR angiography in less than 4 minutes. *Radiology* 2002;**223**:270–4.
84. Sondergaard L, Lindvig K, Hildebrandt P et al. Quantification of aortic regurgitation by magnetic resonance velocity mapping. *Am Heart J* 1993;**125**:1081–90.
85. Tscholakoff D, Sechtem U, de Geer G et al. Evaluation of pleural and pericardial effusions by magnetic resonance imaging. *Eur J Radiol* 1987;**7**:169–74.
86. Deutsch HJ, Sechtem U, Meyer H et al. Chronic aortic dissection: comparison of MR Imaging and transesophageal echocardiography. *Radiology* 1994;**192**:645–50.
87. Kawamoto S, Bluemke DA, Traill TA et al. Thoracoabdominal aorta in Marfan syndrome: MR imaging findings of progression of vasculopathy after surgical repair. *Radiology* 1997;**203**:727–32.
88. Fattori R, Nienaber CA. MRI of acute and chronic aortic pathology: pre-operative and postoperative evaluation. *J Magn Reson Imaging* 1999;**10**:741–50.
89. Murray JG, Manisali M, Flamm SD et al. Intramural hematoma of the thoracic aorta: MR image findings and their prognostic implications. *Radiology* 1997;**204**:349–55.
90. Ionescu AA, Vinereanu D, Wood A et al. Periaortic fat pad mimicking an intramural hematoma of the thoracic aorta: lessons for transesophageal echocardiography. *J Am Soc Echocardiogr* 1998;**11**:487–90.
91. Hayashi H, Matsuoka Y, Sakamoto I et al. Penetrating atherosclerotic ulcer of the aorta: imaging features and disease concept. *Radiographics* 2000;**20**:995–1005.
92. Yucel EK, Steinberg FL, Egglin TK et al. Penetrating aortic ulcers: diagnosis with MR imaging. *Radiology* 1990;**177**:779–81.
93. Troxler M, Mavor AI, Homer-Vanniasinkam S. Penetrating atherosclerotic ulcers of the aorta. *Br J Surg* 2001;**88**:1169–77.
94. Tunick PA, Kronzon I. Atheromas of the thoracic aorta: clinical and therapeutic update. *J Am Coll Cardiol* 2000;**35**:545–54.
95. Helft G, Worthley SG, Fuster V et al. Progression and regression of atherosclerotic lesions: monitoring with serial noninvasive magnetic resonance imaging. *Circulation* 2002;**105**:993–8.
96. Fayad ZA, Nahar T, Fallon JT et al. In vivo magnetic resonance evaluation of atherosclerotic plaques in the human thoracic aorta: a comparison with transesophageal echocardiography. *Circulation* 2000;**101**:2503–9.
97. Goyen M, Laub G, Ladd ME et al. Dynamic 3D MR angiography of the pulmonary arteries in under four seconds. *J Magn Reson Imaging* 2001;**13**:372–7.
98. Oudkerk M, van Beek EJ, Wielopolski P et al. Comparison of contrast-enhanced magnetic resonance angiography and conventional pulmonary angiography for the diagnosis of pulmonary embolism: a prospective study. *Lancet* 2002;**359**:1643–7.
99. Ugolini P, Mousseaux E, Sadou Y et al. Idiopathic dilatation of the pulmonary artery: report of four cases. *Magn Reson Imaging* 1999;**17**:933–7.
100. Stern EJ, Graham C, Gamsu G et al. Pulmonary artery dissection: MR findings. *J Comput Assist Tomogr* 1992;**16**:481–3.
101. Owen RS, Carpenter JP, Baum RA et al. Magnetic resonance imaging of angiographically occult runoff vessels in peripheral arterial occlusive disease. *N Engl J Med* 1992;**326**: 1577–81.
102. Ruehm SG, Goyen M, Barkhausen J et al. Rapid magnetic resonance angiography for detection of atherosclerosis. *Lancet* 2001;**357**:1086–91.
103. Dorweiler B, Neufang A, Kreitner KF et al. Magnetic resonance angiography unmasks reliable target vessels for pedal bypass grafting in patients with diabetes mellitus. *J Vasc Surg* 2002;**35**:766–72.
104. Leyendecker JR, Elsass KD, Johnson SP et al. The role of infrapopliteal MR angiography in patients undergoing optimal contrast angiography for chronic limb-threatening ischemia. *J Vasc Interv Radiol* 1998;**9**:545–51.
105. Cosottini M, Zampa V, Petruzzi P et al. Contrast-enhanced three-dimensional MR angiography in the assessment of subclavian artery diseases. *Eur Radiol* 2000;**10**:1737–44.
106. Wentz KU, Frohlich JM, von Weymarn C et al. High-resolution magnetic resonance angiography of hands with timed arterial compression (tac-MRA). *Lancet* 2003;**361**:49–50.
107. Leung DA, Hagspiel KD, Angle JF et al. MR angiography of the renal arteries. *Radiol Clin North Am* 2002;**40**:847–65.
108. Mittal TK, Evans C, Perkins T et al. Renal arteriography using gadolinium enhanced 3D MR angiography – clinical experience with the technique, its limitations and pitfalls. *Br J Radiol* 2001;**74**:495–502.

109. Vallee JP, Lazeyras F, Khan HG et al. Absolute renal blood flow quantification by dynamic MRI and Gd-DTPA. *Eur Radiol* 2000;**10**:1245–52.
110. Hagspiel KD, Leung DA, Angle JF et al. MR angiography of the mesenteric vasculature. *Radiol Clin North Am* 2002;**40**:867–86.
111. Nederkoorn PJ, Elgersma OE, Mali WP et al. Overestimation of carotid artery stenosis with magnetic resonance angiography compared with digital subtraction angiography. *J Vasc Surg* 2002;**36**:806–13.
112. Fellner FA, Fellner C, Wutke R et al. Fluoroscopically triggered contrast-enhanced 3D MR DSA and 3D time-of-flight turbo MRA of the carotid arteries: first clinical experiences in correlation with ultrasound, X-ray angiography, and endarterectomy findings. *Magn Reson Imaging* 2000;**18**:575–85.
113. Glagov S, Weisenberg E, Zarins CK et al. Compensatory Enlargement of Human Atherosclerotic Coronary Arteries. *N Engl J Med* 1987;**316**:1371–5.
114. Fayad ZA, Nahar T, Fallon JT et al. In vivo magnetic resonance evaluation of atherosclerotic plaques in the human thoracic aorta. A comparison with transesophageal echocardiography. *Circulation* 2000;**101**:2503–9.
115. Yuan C, Beach KW, Smith LH et al. Measurement of atherosclerotic carotid plaque size in-vivo using high resolution magnetic resonance imaging. *Circulation* 1998;**98**:2666–71.
116. Shinnar M, Fallon JT, Wehrli S et al. The diagnostic accuracy of ex vivo MRI for human atherosclerotic plaque characterization. *Arterioscler Thromb Vasc Biol* 1999;**19**:2756–61.
117. Coombs BD, Rapp JH, Ursell PC et al. Structure of plaque at carotid bifurcation: high-resolution MRI with histological correlation. *Stroke* 2001;**32**:2516–21.
118. Cai JM, Hatsukami TS, Ferguson MS et al. Classification of human carotid atherosclerotic lesions with in vivo multicontrast magnetic resonance imaging. *Circulation* 2002;**106**:1368–73.
119. Fayad ZA, Fuster V. Characterization of atherosclerotic plaques by magnetic resonance imaging. *Ann N Y Acad Sci* 2000;**902**: 173–86.
120. Yuan C, Mitsumori LM, Ferguson MS et al. In vivo accuracy of multispectral magnetic resonance imaging for identifying lipid-rich necrotic cores and intraplaque hemorrhage in advanced human carotid plaques. *Circulation* 2001;**104**:2051–6.
121. Mitsumori LM, Hatsukami TS, Ferguson MS et al. In vivo accuracy of multisequence MR imaging for identifying unstable fibrous caps in advanced human carotid plaques. *J Magn Reson Imaging* 2003;**17**:410–20.
122. Yuan C, Zhang SX, Polissar NL et al. Identification of fibrous cap rupture with magnetic resonance imaging is highly associated with recent transient ischemic attack or stroke. *Circulation* 2002;**105**:181–5.
123. Schmitz SA, Taupitz M, Wagner S et al. Magnetic resonance imaging of atherosclerotic plaques using superparamagnetic iron oxide particles. *J Magn Reson Imaging* 2001;**14**:355–61.
124. Ruehm SG, Corot C, Vogt P et al. Magnetic resonance imaging of atherosclerotic plaque with ultrasmall superparamagnetic particles of iron oxide in hyperlipidemic rabbits. *Circulation* 2001;**103**:415–22.
125. Kerwin W, Hooker A, Spilker M et al. Quantitative magnetic resonance imaging analysis of neovasculature volume in carotid atherosclerotic plaque. *Circulation* 2003;**107**:851–6.
126. Wasserman BA, Smith WI, Trout 3rd HH et al. Carotid artery atherosclerosis: in vivo morphologic characterization with gadolinium-enhanced double-oblique MR imaging initial results. *Radiology* 2002;**223**:566–73.
127. Corti R, Fayad ZA, Fuster V et al. Effects of lipid lowering by simvastatin on human atherosclerotic lesions. A longitudinal study by high resolution, non-invasive magnetic resonance imaging. *Circulation* 2001;**104**:249–52.
128. Corti R, Fuster V, Fayad ZA et al. Lipid lowering by simvastatin induces regression of human atherosclerotic lesions: two years' follow-up by high-resolution noninvasive magnetic resonance imaging. *Circulation* 2002;**106**:2884–7.
129. Zhao XQ, Yuan C, Hatsukami TS et al. Effects of prolonged intensive lipid-lowering therapy on the characteristics of carotid atherosclerotic plaques in vivo by MRI: a case-control study. *Arterioscler Thromb Vasc Biol* 2001;**21**:1623–9.
130. Fayad ZA, Fuster V, Fallon JT et al. Noninvasive in vivo human coronary artery lumen and wall imaging using black-blood magnetic resonance imaging. *Circulation* 2000;**102**:506–10.
131. Botnar RM, Stuber M, Kissinger KV et al. Non-invasive coronary vessel wall and plaque imaging using MRI. *Circulation* 2000;**102**:2582–7.
132. Botnar RM, Kim WY, Bornert P et al. 3D coronary vessel wall imaging utilizing a local inversion technique with spiral image acquisition. *Magn Reson Med* 2001;**46**:848–54.
133. Kim WY, Stuber M, Bornert P et al. Three-dimensional black-blood cardiac magnetic resonance coronary vessel wall imaging detects positive arterial remodeling in patients with nonsignificant coronary artery disease. *Circulation* 2002;**106**:296–9.
134. Celermajer DS, Sorensen KE, Gooch VM et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. *Lancet* 1992;**340**:1111–5.
135. Sorenson MB, Collins P, Ong PJL et al. Long term use of contraceptive depot medroxyprogesterone acetate in young women impairs arterial endothelial function assessed by cardiovascular magnetic resonance. *Circulation* 2002;**106**:1646–51.
136. Silber HA, Bluemke DA, Ouyang P et al. The relationship between vascular wall shear stress and flow-mediated dilation: endothelial function assessed by phase-contrast magnetic resonance angiography. *J Am Coll Cardiol* 2001;**38**:1859–65.
137. Mohiaddin RH, Gatehouse PD, Moon JC et al. Assessment of reactive hyperaemia using real time zonal echo-planar flow imaging. *J Cardiovasc Magn Reson* 2002;**4**:283–7.
138. Longmore DB, Klipstein RH, Underwood SR et al. Dimensional accuracy of magnetic resonance in studies of the heart. *Lancet* 1985;**1**:1360–2.
139. Rehr RB, Malloy CR, Filipchuk NG et al. Left ventricular volumes measured by MR imaging. *Radiology* 1985;**156**:717–9.
140. Sechtem U, Pflugfelder PW, Gould RG et al. Measurement of right and left ventricular volumes in healthy individuals with cine MR imaging. *Radiology* 1987;**163**:697–702.
141. Helbing WA, Rebergen SA, Maliepaard C et al. Quantification of right ventricular function with magnetic resonance imaging in children with normal hearts and with congenital heart disease. *Am Heart J* 1995;**130**:828–37.
142. Bryant DJ, Payne JA, Firmin DN et al. Measurement of flow with NMR imaging using a gradient pulse and phase difference technique. *J Comput Assist Tomogr* 1984;**8**:588–93.
143. Nayler GL, Firmin DN, Longmore DB. Blood flow imaging by cine magnetic resonance. *J Comput Assist Tomogr* 1986;**10**:715–22.
144. Firmin DN, Nayler GL, Klipstein RH et al. In vivo validation of magnetic resonance velocity imaging. *J Comput Assist Tomogr* 1987;**11**:751–6.
145. Kondo C, Caputo GR, Semelka R et al. Right and left ventricular stroke volume measurements with velocity encoded cine MR imaging: In vitro and in vivo validation. *Am J Roentgenol* 1991;**157**:9–16.
146. Jauhainen T, Jarvinen VM, Hekali PE et al. MR gradient echo volumetric analysis of human cardiac casts: Focus on the right ventricle. *J Comput Assist Tomogr* 1998;**22**:899–903.
147. Myerson SG, Bellenger NG, Pennell DJ. Assessment of left ventricular mass by cardiovascular magnetic resonance. *Hypertension* 2002;**39**:750–5.
148. Katz J, Millikem MC, Stray-Gunderson J et al. Estimation of human myocardial mass with MR imaging. *Radiology* 1988;**169**:495–8.
149. Bottini PB, Carr AA, Prisant M et al. Magnetic resonance imaging compared to echocardiography to assess left ventricular mass in the hypertensive patient. *Am J Hypertens* 1995;**8**:221–8.
150. Florentine MS, Grosskreutz CL, Chang W et al. Measurement of left ventricular mass in vivo using gated nuclear magnetic resonance imaging. *J Am Coll Cardiol* 1986;**8**:107–12.
151. Keller AM, Peshock RM, Malloy CR et al. In vivo measurement of myocardial mass using nuclear magnetic resonance imaging. *J Am Coll Cardiol* 1986;**8**:113–7.
152. Shapiro EP, Rogers WJ, Beyar R et al. Determination of left ventricular mass by magnetic resonance imaging in hearts deformed by acute infarction. *Circulation* 1989;**79**:706–11.
153. McDonald KM, Francis GS, Matthews J et al. Long term oral nitrate therapy prevents chronic ventricular remodelling in the dog. *J Am Coll Cardiol* 1993;**21**:514–22.

154. Lorenz CH, Walker ES, Morgan VL et al. Normal human right and left ventricular mass, systolic function and gender differences by cine magnetic resonance imaging. *J Cardiovasc Magn Reson* 1999;**1**:7–21.
155. Katz J, Whang J, Boxt LM et al. Estimation of right ventricular mass in normal subjects and in patients with primary pulmonary hypertension by nuclear magnetic resonance imaging. *J Am Coll Cardiol* 1993;**21**:1475–81.
156. McDonald KM, Parrish T, Wennberg P et al. Rapid, accurate and simultaneous noninvasive assessment of right and left ventricular mass with nuclear magnetic resonance imaging using the shapshot gradient method. *J Am Coll Cardiol* 1992;**19**:1601–7.
157. Bloomgarden DC, Fayad ZA, Ferrari VA et al. Global cardiac function using breath-hold MRI: Validation of new acquisition and analysis techniques. *Magn Reson Med* 1997;**37**:683–92.
158. Bellenger NG, Burgess M, Ray SG et al. Comparison of left ventricular ejection fraction and volumes in heart failure by two-dimensional echocardiography, radionuclide ventriculography and cardiovascular magnetic resonance: are they interchangeable. *Eur Heart J* 2000;**21**:1387–96.
159. Semelka RC, Tomei E, Wagner S et al. Normal left ventricular dimensions and function: interstudy reproducibility of measurements with cine MR imaging. *Radiology* 1990;**174**:763–8.
160. Semelka RC, Tomei E, Wagner S et al. Interstudy reproducibility of dimensional and functional measurements between cine magnetic resonance studies in the morphologically abnormal left ventricle. *Am Heart J* 1990;**119**:1367–73.
161. Germain P, Roul G, Kastler B et al. Interstudy variability in left ventricular mass measurement. Comparison between m-mode echography and MRI. *Eur Heart J* 1992;**13**:1011–9.
162. Mogelvang J, Lindvig K, Sondergaard L et al. Reproducibility of cardiac volume measurements including left ventricular mass determined by MRI. *Clin Physiol* 1993;**13**:587–97.
163. Bellenger NG, Davies LC, Francis JM et al. Reduction in sample size for studies of remodelling in heart failure by the use of cardiovascular magnetic resonance. *J Cardiovasc Magn Reson* 2000;**2**:271–8.
164. Osterziel KJ, Strohm O, Schuler J et al. Randomised, double-blind, placebo-controlled trial of human recombinant growth hormone in patients with chronic heart failure due to dilated cardiomyopathy. *Lancet* 1998;**351**:1233–7.
165. Bellenger NG, Rajappan K, Rahman SL et al. Effects of carvedilol on left ventricular remodelling in chronic stable heart failure: a cardiovascular magnetic resonance study. *Heart* 2004;**90**:760–4.
166. Johnson RA, Rubin LJ. Noninvasive evaluation of right ventricular function. *Clin Chest Med* 1987;**8**:65–80.
167. Suzuki J, Caputo GR, Masui T et al. Assessment of right ventricular diastolic and systolic function in patients with dilated cardiomyopathy using cine magnetic resonance imaging. *Am Heart J* 1991;**122**:1035–40.
168. Underwood SR, Rees RSO, Savage PE et al. Assessment of regional left ventricular function by magnetic resonance. *Br Heart J* 1986;**56**:334–40.
169. Peshock RM, Rokey R, Malloy GM et al. Assessment of myocardial systolic wall thickening using nuclear magnetic resonance imaging. *J Am Coll Cardiol* 1989;**14**:653–9.
170. Azhari H, Sideman S, Weiss JL et al. Three-dimensional mapping of acute ischemic regions using MRI: wall thickening versus motion analysis. *Am J Physiol* 1990;**259**:H1492–503.
171. Sechtem U, Sommerhoff BA, Markiewicz W et al. Regional left ventricular wall thickening by magnetic resonance imaging: evaluation of normal persons and patients with global and regional dysfunction. *Am J Cardiol* 1987;**59**:145–51.
172. Zerhouni EA, Parish DM, Rogers WJ et al. Human heart: Tagging with MR Imaging- A method for non-invasive assessment of myocardial motion. *Radiology* 1988;**169**:59–63.
173. Buchalter MB, Weiss JL, Rogers WJ et al. Noninvasive quantification of left ventricular rotational deformation in normal humans using magnetic resonance imaging myocardial tagging. *Circulation* 1990;**81**:1236–44.
174. Young AA, Axel L. Three dimensional motion and deformation of the heart wall: Estimation with spatial modulation of magnetisation – a model based approach. *Radiology* 1992;**185**:241–7.
175. Lima JA, Jeremy R, Guier W et al. Accurate systolic wall thickening by nuclear magnetic resonance imaging with tissue tagging: correlation with sonomicrometers in normal and ischemic myocardium. *J Am Coll Cardiol* 1993;**21**:1741–51.
176. Gotte MJ, van Rossum AC, Twisk JWR et al. Quantification of regional contractile function after infarction: strain analysis superior to wall thickening analysis in discriminating infarct from remote myocardium. *J Am Coll Cardiol* 2001;**37**:808–17.
177. Pennell DJ, Underwood SR, Manzara CC et al. Magnetic resonance imaging during dobutamine stress in coronary artery disease. *Am J Cardiol* 1992;**70**:34–40.
178. Baer FM, Voth E, Theissen P et al. Coronary artery disease: findings with GRE MR imaging and Tc-99m-methoxyisobutyl-isonitrile SPECT during simultaneous dobutamine stress. *Radiology* 1994;**193**:203–9.
179. Baer FM, Voth E, Theissen P et al. Gradient-echo magnetic resonance imaging during incremental dobutamine infusion for the localization of coronary artery stenoses. *Eur Heart J* 1994;**15**:218–25.
180. van Rugge FP, van der Wall EE, de Roos A et al. Dobutamine stress magnetic resonance imaging for detection of coronary artery disease. *J Am Coll Cardiol* 1993;**22**:431–9.
181. Pennell DJ, Underwood SR, Ell PJ et al. Dipyridamole magnetic resonance imaging: a comparison with thallium-201 emission tomography. *Br Heart J* 1990;**64**:362–9.
182. Casolo GC, Bonechi F, Taddei T et al. Alterations in dipyridamole induced LV wall motion during myocardial ischaemia studied by NMR imaging. Comparison with Tc-99m-MIBI myocardial scintigraphy. *G Ital Cardiol* 1991;**21**:609–17.
183. Baer FM, Smolarz K, Jungehulsing M et al. Feasibility of high dose dipyridamole magnetic resonance imaging for detection of coronary artery disease and comparison with coronary angiography. *Am J Cardiol* 1992;**69**:51–6.
184. Baer FM, Smolarz K, Theissen P et al. Identification of haemodynamically significant coronary stenoses by dipyridamole magnetic resonance imaging and 99mTc methoxyisobutyl-isonitrile SPECT. *Int J Card Imaging* 1993;**9**:133–45.
185. Zhao S, Croisille P, Janier M et al. Comparison between qualitative and quantitative wall motion analyses using dipyridamole stress breath-hold cine MRI in patients with severe coronary artery stenosis. *Magn Reson Imaging* 1997;**15**:891–8.
186. Nagel E, Lorenz C, Baer F et al. Stress cardiovascular magnetic resonance: consensus panel report. *J Cardiovasc Magn Reson* 2001;**3**:267–81.
187. Nagel E, Lehmkuhl HB, Bocksch W et al. Noninvasive diagnosis of ischemia induced wall motion abnormalities with the use of high dose dobutamine stress MRI. Comparison with dobutamine stress echocardiography. *Circulation* 1999;**99**:763–70.
188. Nagel E, Lehmkuhl HB, Klein C et al. Influence of image quality on the diagnostic accuracy of dobutamine stress magnetic resonance imaging in comparison with dobutamine stress echocardiography for the non-invasive detection of myocardial ischemia. *Z Kardiol* 1999;**88**:622–30.
189. Hundley WG, Hamilton CA, Thaomas MS et al. Utility of fast cine magnetic resonance imaging and display for the detection of myocardial ischemia in patients not well suited for second harmonic stress echocardiography. *Circulation* 1999;**100**:1697–702.
190. van Rugge FP, van der Wall EE, Spanjersberg SJ et al. Magnetic resonance imaging during dobutamine stress for detection and localization of coronary artery disease. Quantitative wall motion analysis using a modification of the centerline method. *Circulation* 1994;**90**:127–38.
191. Hundley WG, Morgan TM, Neagle CM et al. Magnetic resonance imaging determination of cardiac prognosis. *Circulation* 2002;**106**:2328–33.
192. Kuijpers D, Ho KY, van Dijkman PR et al. Dobutamine cardiovascular magnetic resonance for the detection of myocardial ischemia with the use of myocardial tagging. *Circulation* 2003;**107**:1592–7.
193. Rerkpattanapipat P, Morgan TM, Neagle CM et al. Assessment of preoperative cardiac risk with magnetic resonance imaging. *Am J Cardiol* 2002;**90**:416–9.
194. Power TP, Kramer CM, Shaffer AL et al. Breath-hold dobutamine magnetic resonance myocardial tagging: normal left ventricular response. *Am J Cardiol* 1997;**80**:1203–7.
195. Scott CH, Sutton St John, Gusani N et al. Effect of dobutamine on regional left ventricular function measured by tagged magnetic

resonance imaging in normal subjects. *Am J Cardiol* 1999;**83**:412–7.
196. Hoffmann R, Lethen H, Marwick T et al. Analysis of interinstitutional observer agreement in interpretation of dobutamine stress echocardiograms. *J Am Coll Cardiol* 1996;**27**:330–6.
197. Schalla S, Klein C, Paetsch I et al. Real-time MR image acquisition during high-dose dobutamine hydrochloride stress for detecting left ventricular wall motion abnormalities in patients with coronary arterial disease. *Radiology* 2002;**224**:845–51.
198. Karwatowski SP, Mohiaddin RH et al. Noninvasive assessment of regional left ventricular long axis motion using magnetic resonance velocity mapping in normal subjects. *J Magn Reson Imaging* 1994;**4**:151–5.
199. Karwatowski SP, Mohiaddin RH, Yang GZ et al. Regional myocardial velocity imaged by magnetic resonance in patients with ischaemic heart disease. *Br Heart J* 1994;**72**:332–8.
200. Pennell DJ, Firmin DN, Burger P et al. Assessment of magnetic resonance velocity mapping of global ventricular function during dobutamine infusion in coronary artery disease. *Br Heart J* 1995;**74**:163–70.
201. Panting JR, Gatehouse PD, Yang GZ et al. Echo planar magnetic resonance myocardial perfusion imaging: Parametric map analysis and comparison with thallium SPECT. *J Magn Reson Imaging* 2001;**13**:192–200.
202. Schwitter J, Nanz D, Kneifel S et al. Assessment of myocardial perfusion in coronary artery disease by magnetic resonance: a comparison with positron emission tomography and coronary angiography. *Circulation* 2001;**103**:2230–5.
203. Yang GZ, Burger P, Panting JR et al. Motion and deformation tracking for short axis echo planar myocardial perfusion imaging. *Med Imag Anal* 1998;**2**:285–302.
204. Jerosch-Herold M, Wilke N, Stillman AE et al. Magnetic resonance quantification of the myocardial perfusion reserve with a Fermi function model for constrained deconvolution. *Med Phys* 1998;**25**:73–84.
205. Wilke N, Jerosch-Herold M et al. Concepts of myocardial perfusion in magnetic resonance imaging. *Magn Reson Q* 1994;**10**:249–86.
206. Kroll K, Wilke N, Jerosch-Herold M et al. Modelling regional myocardial flows from residue functions of an intravascular indicator. *Am J Physiol* 1996;**271**:H1643–55.
207. Wilke N, Simm C, Zhang J et al. Contrast enhanced first pass myocardial perfusion imaging: Correlation between myocardial blood flow in dogs at rest and during hyperemia. *Magn Reson Med* 1993;**29**:485–97.
208. Epstein FH, London JF, Peters DC et al. Multislice first pass cardiac perfusion MRI: Validation in a model of myocardial infarction. *Magn Reson Med* 2002;**47**:482–91.
209. Kraitchman DL, Wilke N, Hexeberg E et al. Myocardial perfusion and function in dogs with moderate coronary stenosis. *Magn Reson Med* 1996;**35**:771–80.
210. Cullen JHS, Horsfield MA, Reek CR et al. A myocardial perfusion reserve index in humans using contrast enhanced magnetic resonance imaging. *J Am Coll Cardiol* 1999;**33**:1386–94.
211. Al-Saadi N, Nagel E, Gross M et al. Noninvasive detection of myocardial ischemia from perfusion reserve based on cardiovascular magnetic resonance. *Circulation* 2000;**101**:1379–83.
212. Wolff SD, Schwitter J, Coulden R et al. Myocardial first-pass perfusion magnetic resonance imaging. A Multicenter dose-ranging study. *Circulation* 2004;**110**:732–7.
213. Al-Saadi N, Nagel E, Gross M et al. Improvement of myocardial perfusion reserve early after coronary intervention: assessment with cardiac magnetic resonance imaging. *J Am Coll Cardiol* 2000;**36**:1557–64.
214. Sipola P, Lauerma K, Husso-Saastamoinen M et al. First-pass MR imaging in the assessment of perfusion impairment in patients with hypertrophic cardiomyopathy and the Asp175Asn mutation of the alpha-tropomyosin gene. *Radiology* 2003;**226**:129–37.
215. Panting JR, Gatehouse PD, Yang GZ et al. Abnormal subendocardial perfusion in cardiac syndrome-X detected by cardiovascular magnetic resonance imaging. *N Engl J Med* 2002;**346**:1948–53.
216. Bauer WR, Nadler W, Bock M et al. The relationship between the BOLD-induced T (2) and T (2) (*): a theoretical approach for the vasculature of myocardium. *Magn Reson Med* 1999;**42**:1004–10.
217. Beache GM, Herzka DA, Boxerman JL et al. Attenuated myocardial vasodilator response in patients with hypertensive hypertrophy revealed by oxygenation-dependent magnetic resonance imaging. *Circulation* 2001;**104**:1214–7.
218. Wright KB, Klocke FJ, Deshpande VS et al. Assessment of regional differences in myocardial blood flow using T2-weighted 3D BOLD imaging. *Magn Reson Med* 2001;**46**:573–8.
219. Wacker CM, Hartlep AW, Pfleger S et al. Susceptibility-sensitive magnetic resonance imaging detects human myocardium supplied by a stenotic coronary artery without a contrast agent. *J Am Coll Cardiol* 2003;**41**:834–40.
220. Friedrich MG, Niendorf T, Schulz-Menger J et al. Blood oxygen level-dependent magnetic resonance imaging in patients with stress-induced angina. *Circulation* 2003;**108**:2219–23.
221. Wielopolski PA, van Geuns, de Feyter PJ et al. Breath-hold coronary MR angiography with volume-targeted imaging. *Radiology* 1998;**209**:209–19.
222. Botnar RM, Stuber M, Danias PG et al. Improved coronary artery definition with T2-weighted, free breathing, three dimensional coronary MRA. *Circulation* 1999;**99**:3139–48.
223. Kim WY, Danias PG, Stuber M et al. Coronary magnetic resonance angiography for the detection of coronary stenosis. *N Engl J Med* 2001;**345**:1863–9.
224. Keegan J, Firmin D, Gatehouse P et al. The application of breath hold phase velocity mapping techniques to the measurement of coronary artery blood flow velocity: phantom data and initial in vivo results. *Magn Reson Med* 1994;**31**:526–36.
225. Hofman MB, Visser FC, van Rossum AC et al. In vivo validation of magnetic resonance blood volume flow measurements with limited spatial resolution in small vessels. *Magn Reson Med* 1995;**33**:778–84.
226. Clarke GD, Eckels R, Chaney C et al. Measurement of absolute epicardial coronary artery flow and flow reserve with breath-hold cine phase-contrast magnetic resonance imaging. *Circulation* 1995;**91**:2627–34.
227. Hundley WG, Lange RA, Clarke GD et al. Assessment of coronary arterial flow and flow reserve in humans with magnetic resonance imaging. *Circulation* 1996;**93**:1502–8.
228. Sakuma H, Blake LM, Amidon TM et al. Coronary flow reserve: noninvasive measurement in humans with breath-hold velocity encoded cine MR imaging. *Radiology* 1996;**198**:745–50.
229. Davis CP, Liu PF, Hauser M et al. Coronary flow and coronary flow reserve measurements in humans with breath-held magnetic resonance contrast velocity mapping. *Magn Reson Med* 1997;**37**:537–44.
230. Hundley WG, Hamilton CA et al. Visualisation and functional assessment of proximal and middle left anterior descending coronary stenosis in humans with magnetic resonance imaging. *Circulation* 1999;**99**:3248–54.
231. Nagel E, Thouet T, Klein C et al. Noninvasive determination of coronary blood flow velocity with cardiovascular magnetic resonance in patients after stent deployment. *Circulation* 2003;**107**:1738–43.
232. Gomes AS, Lois JF, Drinkwater DC et al. Coronary artery bypass grafts: visualization with MR imaging. *Radiology* 1987;**162**:175–9.
233. Jenkins JPR, Love HG, Foster CJ et al. Detection of coronary bypass graft patency as assessed by magnetic resonance imaging. *Br J Radiol* 1988;**61**:2–4.
234. White RD, Caputo GR, Mark AS et al. Coronary artery bypass graft patency: noninvasive evaluation with MR imaging. *Radiology* 1987;**164**:681–6.
235. Aurigemma GP, Reichek N, Axel L et al. Noninvasive determination of coronary artery bypass graft patency by cine magnetic resonance imaging. *Circulation* 1989;**80**:1595–602.
236. Hoogendoorn LI, Pattynama PM, Buis B et al. Noninvasive evaluation of aortocoronary bypass grafts with magnetic resonance flow mapping. *Am J Cardiol* 1995;**75**:845–8.
237. Galjee MA, van Rossum AC, Doesburg T et al. Value of magnetic resonance imaging in assessing patency and function of coronary artery bypass grafts: An angiographically controlled study. *Circulation* 1996;**93**:660–6.
238. Langerak SE, Kunz P, Vliegen HW et al. MR flow mapping in coronary artery bypass grafts: a validation study with Doppler flow measurements. *Radiology* 2002;**222**:127–35.

239. Langerak SE, Vliegen HW, de Roos A et al. Detection of vein graft disease using high-resolution magnetic resonance angiography. *Circulation* 2002;**105**:328–33.
240. Langerak SE, Vliegen HW, Jukema JW et al. Value of magnetic resonance imaging for the noninvasive detection of stenosis in coronary artery bypass grafts and recipient coronary arteries. *Circulation* 2003;**107**:1502–8.
241. Bedaux WL, Hofman MB, Vyt SL et al. Assessment of coronary artery bypass graft disease using cardiovascular magnetic resonance determination of flow reserve. *J Am Coll Cardiol* 2002;**40**:1848–55.
242. Simonetti OP, Kim RJ, Fieno DS et al. An improved MR imaging technique for the visualization of myocardial infarction. *Radiology* 2001;**218**:215–23.
243. Judd RM, Lugo-Olivieri CH, Arai M et al. Physiological basis of myocardial contrast enhancement in fast magnetic resonance images of 2-day-old reperfused canine infarcts. *Circulation* 1995;**92**:1902–10.
244. Kim RJ, Chen EL, Lima JAC et al. Myocardial Gd-DTPA kinetics determine MRI contrast enhancement and reflect the extent and severity of myocardial injury after acute reperfused infarction. *Circulation* 1996;**94**:3318–26.
245. Kim RJ, Fieno DS, Parrish RB et al. Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function. *Circulation* 1999;**100**:185–92.
246. Fieno DS, Kim RJ, Chen EL et al. Contrast-enhanced magnetic resonance imaging of myocardium at risk: distinction between reversible and irreversible injury throughout infarct healing. *J Am Coll Cardiol* 2000;**36**:1985–91.
247. Wu E, Judd RM, Vargas JD et al. Visualisation of presence, location, and transmural extent of healed Q-wave and non-Q-wave Myocardial infarction. *Lancet* 2001;**357**:21–8.
248. Wagner A, Mahrholdt H, Holly TA et al. Contrast-enhanced MRI and routine single photon emission computed tomography (SPECT) perfusion imaging for detection of subendocardial myocardial infarcts: an imaging study. *Lancet* 2003;**361**:374–9.
249. Dubnow MH, Burchell HB, Titus JL. Postinfarction left ventricular aneurysm. A clinicomorphologic and electrocardiographic study of 80 cases. *Am Heart J* 1965;**70**:753–60.
250. Baer FM, Voth E, Schneider CA et al. Comparison of low-dose dobutamine-gradient-echo magnetic resonance imaging and positron emission tomography with [18F]fluorodeoxyglucose in patients with chronic coronary artery disease. A functional and morphological approach to the detection of residual myocardial viability. *Circulation* 1995;**91**:1006–15.
251. Ramani K, Judd RM, Holly TA et al. Contrast magnetic resonance imaging in the assessment of myocardial viability in patients with stable coronary artery disease and left ventricular dysfunction. *Circulation* 1998;**98**:2687–94.
252. Gerber BL, Garot J, Bluemke DA et al. Accuracy of contrast-enhanced magnetic resonance imaging in predicting improvement of regional myocardial function in patients after acute myocardial infarction. *Circulation* 2002;**106**:1083–9.
253. Kim RJ, Wu E, Rafael A et al. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. *N Engl J Med* 2000;**16**:1445–53.
254. Mahrholdt H, Wagner A, Holly TA et al. Reproducibility of chronic infarct size measurement by contrast-enhanced magnetic resonance imaging. *Circulation* 2002;**106**:2322–7.
255. Klein C, Nekolla SG, Bengel FM et al. Assessment of myocardial viability with contrast-enhanced magnetic resonance imaging: comparison with positron emission tomography. *Circulation* 2002;**105**:162–7.
256. Kuhl HP, Beek AM, van der Weerdt AP et al. Myocardial viability in chronic ischemic heart disease: comparison of contrast-enhanced magnetic resonance imaging with (18)F-fluorodeoxyglucose positron emission tomography. *J Am Coll Cardiol* 2003;**41**:1341–8.
257. Kitagawa K, Sakuma H, Hirano T et al. Acute myocardial infarction: Myocardial viability assessment in patients early thereafter – comparison of contrast enhanced MR imaging with resting ^{201}-Tl SPECT. *Radiology* 2003;**226**:138–44.
258. Kwong RY, Schussheim AE, Rekhraj S et al. Detecting acute coronary syndrome in the emergency department with cardiac magnetic resonance imaging. *Circulation* 2003;**107**:531–7.
259. Wu KC, Kim RJ, Bluemke DA et al. Quantification and time course of microvascular obstruction by contrast-enhanced echocardiography and magnetic resonance imaging following acute myocardial infarction and reperfusion. *J Am Coll Cardiol* 1998;**32**:1756–64.
260. Rochitte CE, Lima JA, Bluemke DA et al. Magnitude and time course of microvascular obstruction and tissue injury after acute myocardial infarction. *Circulation* 1998;**98**:1006–14.
261. Gerber BL, Rochitte CE, Melin JA et al. Microvascular obstruction and left ventricular remodeling early after acute myocardial infarction. *Circulation* 2000;**101**:2734–41.
262. Wu KC, Zerhouni EA, Judd RM et al. Prognostic significance of microvascular obstruction by magnetic resonance imaging in patients with acute myocardial infarction. *Circulation* 1998;**97**:765–72.
263. Choi KM, Kim RJ, Gubernikoff G et al. Transmural extent of acute myocardial infarction predicts long-term improvement in contractile function. *Circulation* 2001;**104**:1101–7.
264. Ahmad M, Johnson RJ, Fawcett HD et al. Left ventricular aneurysm in short axis: a comparison of magnetic resonance, ultrasound and thallium-201 SPECT images. *Magn Reson Imaging* 1987;**5**:293–300.
265. Harrity P, Patel A, Bianco J et al. Improved diagnosis and characterization of postinfarction left ventricular pseudoaneurysm by cardiac magnetic resonance imaging. *Clin Cardiol* 1991;**14**:603–6.
266. Sechtem U, Pflugfelder P, Cassidy MC et al. Ventricular septal defect: visualization of shunt flow and determination of shunt size by cine MR imaging. *Am J Roentgenol* 1987;**149**:689–92.
267. Sechtem U, Theissen P, Heindel W et al. Comparison of magnetic resonance imaging, computed tomography, echocardiography, and angiography in the diagnosis of left ventricular thrombi. *Am J Cardiol* 1989;**64**:1195–9.
268. Jungehuelsing M, Sechtem U, Theissen P et al. Left ventricular thrombi: evaluation with spin-echo and gradient-echo MR imaging. *Radiology* 1992;**182**:225–9.
269. Semelka RC, Shoenut JP, Wilson ME et al. Cardiac masses: signal intensity features on spin-echo, gradient-echo, gadolinium-enhanced spin-echo, and TurboFLASH images. *J Magn Reson Imaging* 1992;**2**:415–20.
270. Mollet NR, Dymarkowski S, Volders W et al. Visualization of ventricular thrombi with contrast-enhanced magnetic resonance imaging in patients with ischemic heart disease. *Circulation* 2002;**106**:2873–6.
271. Devereux RB, Alonso DR, Lutas EM et al. Echocardiographic assessment of left ventricular hypertrophy. *Am J Cardiol* 1986;**57**:450–8.
272. Gardin JM, Dabestani A, Glasgow GA et al. Echocardiographic and doppler flow observations in obstructed and non obstructed hypertrophic cardiomyopathy. *Am J Cardiol* 1985;**56**:614–21.
273. Sardanelli F, Molinari G, Petillo A et al. MRI in hypertrophic cardiomyopathy: a morphofunctional study. *J Comput Assist Tomogr* 1993;**17**:862–72.
274. Moon JCC, Fisher NG et al. Detection of apical hypertrophic cardiomyopathy by cardiovascular magnetic resonance in patients with non-diagnostic echocardiography. *Heart* 2004;**90**:645–9.
275. Higgins CB, Byrd BF, Stark D et al. Magnetic resonance imaging of hypertrophic cardiomyopathy. *Am J Cardiol* 1985;**55**:1121–6.
276. Suzuki J, Watanabe F, Takenaka K et al. New subtype of apical hypertrophic cardiomyopathy identified with nuclear magnetic resonance imaging as an underlying cause of markedly inverted T waves. *J Am Coll Cardiol* 1993;**22**:1175–81.
277. Arrive L, Assayag P, Russ G et al. MRI and cine MRI of asymmetric septal hypertrophic cardiomyopathy. *J Comput Assist Tomogr* 1994;**18**:376–82.
278. Kramer CM, Reichek N, Ferrari VA et al. Regional heterogeneity of function in hypertrophic cardiomyopathy. *Circulation* 1994;**90**:186–94.
279. Young AA, Kramer CM, Ferrari VA et al. Three-dimensional left ventricular deformation in hypertrophic cardiomyopathy. *Circulation* 1994;**90**:854–67.
280. Dong SJ, Macgregor JH, Crawley AP et al. Left ventricular wall thickness and regional systolic function in patients with hypertrophic cardiomyopathy - a three-dimensional tagged magnetic resonance imaging study. *Circulation* 1994;**90**:1200–9.
281. Moon JC, Reed E, Sheppard MA et al. The histological basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy. *J Am Coll Cardiol* 2004;**43**:2260–4.

282. Moon JC, McKenna WJ, McCrohon JA et al. Toward clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance. *J Am Coll Cardiol* 2003;**41**:1561–7.
283. White RD, Obuchowski NA, Gunawardena S et al. Left ventricular outflow tract obstruction in hypertrophic cardiomyopathy: Presurgical and postsurgical evaluation by computed tomography magnetic resonance imaging. *Am J Card Imaging* 1996;**10**:1–13.
284. Sievers B, Moon JC, Pennell DJ. Magnetic resonance contrast enhancement of iatrogenic septal myocardial infarction in hypertrophic cardiomyopathy. *Circulation* 2002;**105**:1018.
285. Moon JC, Sachdev B, Elkington AG et al. Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease: evidence for a disease specific abnormality of the myocardial interstitium. *Eur Heart J* 2003;**24**:2151–5.
286. Myerson SG, Montgomery HE, World MJ et al. Left ventricular mass measurement: Reliability of M-mode and 2-dimensional echocardiographic formulae. *Hypertension* 2002;**40**:673–8.
287. Myerson SG, Montgomery HE, Whittingham M et al. Left ventricular hypertrophy with exercise and the angiotensin converting enzyme gene I/D polymorphism: A randomised controlled trial with Losartan. *Circulation* 2001;**103**:226–30.
288. Brull D, Dhamrait S, Myerson S et al. Bradykinin B2KBR receptor polymorphism and left ventricular growth response. *Lancet* 2001;**358**:1155–6.
289. Eichstaedt H, Danne O, Langer M et al. Regression of left ventricular hypertrophy under ramipril treatment investigated by nuclear magnetic resonance imaging. *J Cardiovasc Pharmacol* 1989;**13**:75–80.
290. Hoffman U, Globits S, Stefenelli T et al. The effects of ACE inhibitor therapy on left ventricular myocardial mass and diastolic filling in previously untreated hypertensive patients: A cine MRI study. *J Magn Reson Imaging* 2001;**14**:16–22.
291. Jenni R, Oechslin E, Schneider J et al. Echocardiographic and pathoanatomical characteristics of isolated left ventricular noncompaction: a step towards classification as a distinct cardiomyopathy. *Heart* 2001;**86**:666–71.
292. Sasse-Klaassen S, Gerull B, Oechslin E et al. Isolated noncompaction of the left ventricular myocardium in the adult is an autosomal dominant disorder in the majority of patients. *Am J Med Genet* 2003;**119A**(2):162–7.
293. Jenni R, Wyss CA, Oechslin EN et al. Isolated ventricular noncompaction is associated with coronary microcirculatory dysfunction. *J Am Coll Cardiol* 2002;**39**:450–4.
294. McCrohon JA, Richmond DR, Pennell DJ et al. Isolated noncompaction of the myocardium – a rarity or missed diagnosis?. *Circulation* 2002;**106**:e22–3.
295. McCrohon JA, Moon JC, Prasad SK et al. Differentiation of heart failure related to dilated cardiomyopathy and coronary artery disease using gadolinium enhanced cardiovascular magnetic resonance. *Circulation* 2003;**108**:54–9.
296. Doherty NE, Fujita N, Caputo GR et al. Measurement of right ventricular mass in normal and dilated cardiomyopathic ventricles using cine magnetic resonance imaging. *Am J Cardiol* 1992;**69**:1223–8.
297. Doherty NE, Seelos KC, Suzuki J et al. Application of cine nuclear magnetic resonance imaging for sequential evaluation of response to angiotensin-converting enzyme inhibitor therapy in dilated cardiomyopathy. *J Am Coll Cardiol* 1992;**19**:1294–302.
298. Osterziel KJ, Strohm O, Schuler J et al. Randomised, double-blind, placebo-controlled trial of human recombinant growth hormone in patients with chronic heart failure due to dilated cardiomyopathy. *Lancet* 1998;**351**:1233–7.
299. Groenning BA, Nilsson JC, Sondergaard L et al. Antiremodeling effects on the left ventricle during beta-blockade with metoprolol in the treatment of chronic heart failure. *J Am Coll Cardiol* 2000;**36**:2072–80.
300. Casolo GC, Poggesi L, Boddi M et al. ECG-gated magnetic resonance imaging in right ventricular dysplasia. *Am Heart J* 1987;**113**:1245–8.
301. Blake LM, Scheinman MM, Higgins CB. MR features of arrhythmogenic right ventricular dysplasia. *Am J Roentgenol* 1994;**162**:809–12.
302. McKenna WJ, Thiene G, Nava A et al. Diagnosis of arrhythmogenic right ventricular dysplasia/cardiomyopathy. Task Force of the Working Group Myocardial and Pericardial Disease of the European Society of Cardiology and of the Scientific Council on Cardiomyopathies of the International Society and Federation of Cardiology. *Br Heart J* 1994;**71**:215–8.
303. Keller D, Osswald S, Bremerich J et al. Arrhythmogenic right ventricular dysplasia: diagnostic and prognostic value of cardiac MRI in relation to arrhythmia free survival. *Int J Card Imaging* 2003;**19**:537.
304. Weatherall DJ. *Anaemia as a World Health Problem. Oxford textbook of medicine*, vol. 22. Oxford: Oxford University Press; 2001. p. 3463–82.
305. Borgna-Pignatti C, Rugolotto S, De Stefano P et al. Survival and disease complications in thalassemia major. *Ann N Y Acad Sci* 1998;**850**:227–31.
306. Anderson LJ, Holden S, Davis B et al. Cardiovascular T2* magnetic resonance for the early diagnosis of myocardial iron overload. *Eur Heart J* 2001;**22**:2171–9.
307. Anderson LJ, Bunce N, Davis B et al. Reversal of siderotic cardiomyopathy: a prospective study with cardiac magnetic resonance (abstract). *Heart* 2001;**85**(Suppl. 1):33.
308. Anderson LJ, Wonke B, Prescott E et al. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron levels and ventricular function in beta thalassemia. *Lancet* 2002;**360**:516–20.
309. Westwood M, Anderson LJ, Firmin DN et al. A single breath-hold multiecho T2* cardiovascular magnetic resonance technique for diagnosis of myocardial iron overload. *J Magn Reson Imaging* 2003;**18**:616–20.
310. Sechtem U, Higgins CB, Sommerhoff BA et al. Magnetic resonance imaging of restrictive cardiomyopathy. *Am J Cardiol* 1987;**59**:480–2.
311. Fattori R, Rocchi G, Celletti F et al. Contribution of magnetic resonance imaging in the differential diagnosis of cardiac amyloidosis and symmetric hypertrophic cardiomyopathy. *Am Heart J* 1998;**136**:824–30.
312. Masui T, Finck S, Higgins CB. Constrictive pericarditis and restrictive cardiomyopathy: evaluation with MR imaging. *Radiology* 1992;**182**:369–73.
313. Danias PG. Gadolinium-enhanced cardiac magnetic resonance imaging: expanding the spectrum of clinical applications. *Am J Med* 2001;**110**:591–2.
314. Riedy K, Fisher MR, Belic N et al. MR imaging of myocardial sarcoidosis. *Am J Rontgenol* 1988;**15**:915–6.
315. Doherty MJ, Kumar SK, Nicholson AA et al. Cardiac sarcoidosis: the value of magnetic resonance imaging in diagnosis and assessment of response to treatment. *Respir Med* 1998;**92**:797–9.
316. Shimada T, Shimada K, Sakane T et al. Diagnosis of cardiac sarcoidosis and evaluation of the effects of steroid therapy by gadolinium-DTPA-enhanced magnetic resonance imaging. *Am J Med* 2001;**110**:520–7.
317. Schulz-Menger J, Strohm O, Dietz R et al. Visualization of cardiac involvement in patients with systemic sarcoidosis applying contrast-enhanced magnetic resonance imaging. *MAGMA* 2000;**11**:82–3.
318. Vignaux O, Dhote R, Duboc D et al. Clinical significance of myocardial magnetic resonance abnormalities in patients with sarcoidosis: a 1-year follow-up study. *Chest* 2002;**122**:1895–901.
319. Friedrich MG, Strohm O, Schulz-Menger J et al. Contrast media enhanced magnetic resonance imaging visualises myocardial changes in the course of viral myocarditis. *Circulation* 1998;**97**:1802–9.
320. Wagner A, Schulz-Menger J, Dietz R et al. Long term follow-up of patients with acute myocarditis by magnetic resonance imaging. *MAGMA* 2003;**16**:17–20.
321. Mahrholdt H, Goedecke C, Wagner A et al. Cardiovascular magnetic resonance assessment of human myocarditis: a comparison to histology and molecular pathology. *Circulation* 2004;**109**:1250–8.
322. Revel D, Chapelon C, Mathieu D et al. Magnetic resonance imaging of human orthotopic heart transplantation: correlation with endomyocardial biopsy. *J Heart Transplant* 1989;**8**:139–46.
323. Kurland RJ, West J, Kelley S et al. Magnetic resonance imaging to detect heart transplant rejection: sensitivity and specificity. *Transplant Proc* 1989;**21**:2537–43.
324. Marie PY, Carteaux JP, Angioi M et al. Detection and prediction of acute heart transplant rejection: preliminary results on the clinical

use of a black blood magnetic resonance imaging sequence. *Transplant Proc* 1998;**30**:1933–5.
325. Mohiaddin RH, Bogren HG, Lazim F et al. Magnetic resonance coronary angiography in heart transplant recipients. *Coron Artery Dis* 1996;**7**:591–7.
326. Schwitter J, De Marco T, Globits S et al. Influence of felodipine on left ventricular hypertrophy and systolic function in orthotopic heart transplant recipients: possible interaction with cyclosporine medication. *J Heart Lung Transplant* 1999;**18**:1003–13.
327. Globits S, De Marco T, Schwitter J et al. Assessment of early left ventricular remodeling in orthotopic heart transplant recipients with cine magnetic resonance imaging: potential mechanisms. *J Heart Lung Transplant* 1997;**16**:504–10.
328. Mohiaddin RH, Wann SL, Underwood R et al. Vena caval flow: assessment with cine MR velocity mapping. *Radiology* 1990;**177**:537–41.
329. Masui T, Finck S, Higgins CB. Constrictive pericarditis and restrictive cardiomyopathy: evaluation with MR imaging. *Radiology* 1992;**182**:369–73.
330. Sechtem U, Tscholakoff D, Higgins CB. MRI of the abnormal pericardium. *Am J Roentgenol* 1986;**147**:239–44.
331. Kaemmerer H, Theissen P, Konig U et al. Follow-up using magnetic resonance imaging in adult patients after surgery for aortic coarctation. *Thorac Cardiovasc Surg* 1993;**41**:107–11.
332. Ratib O, Perloff JK, Williams WG. Congenital complete absence of the pericardium. *Circulation* 2001;**26**(103):3154–5.
333. Schiavone WA, O'Donnell JK. Congenital absence of the left portion of parietal pericardium demonstrated by nuclear magnetic resonance imaging. *Am J Cardiol* 1985;**55**:1439–40.
334. Freedberg RS, Kronzon I, Rumancik WM et al. The contribution of magnetic resonance imaging to the evaluation of intracardiac tumors diagnosed by echocardiography. *Circulation* 1988;**77**:96–103.
335. Montalescot G, Chapelon C, Drobinski G et al. Diagnosis of primary cardiac sarcoma. Report of 4 cases and review of the literature. *Int J Cardiol* 1988;**20**:209–19.
336. Lund JT, Ehman RL, Julsrud PR et al. Cardiac masses: assessment by MR imaging. *Am J Roentgenol* 1989;**152**:469–73.
337. Semelka RC, Shoenut JP, Wilson ME et al. Cardiac masses: signal intensity features on spin-echo, gradient-echo, gadolinium-enhanced spin-echo, and TurboFLASH images. *J Magn Reson Imaging* 1992;**2**:415–20.
338. Frank H. Cardiac masses. In: Manning WJ, Pennell DJ, editors. *Cardiovascular magnetic resonance*. Philadelphia, USA: Churchill Livingstone; 2002.
339. Arai AE, Epstein FH, Bove KE et al. Visualization of aortic valve leaflets using black blood MRI. *J Magn Reson Imaging* 1999;**10**:771–7.
340. Wagner S, Auffermann W, Buser P et al. Diagnostic accuracy and estimation of the severity of valvular regurgitation from the signal void on cine magnetic resonance images. *Am Heart J* 1989;**118**:760–7.
341. Suzuki J, Caputo GR, Kondo C et al. Cine MR imaging of valvular heart disease: display and imaging parameters affect the size of the signal void caused by valvular regurgitation. *Am J Roentgenol* 1990;**155**:723–7.
342. Kozerke S, Scheidegger MB, Pedersen EM et al. Heart motion adapted cine-phase contrast flow measurements through the aortic valve. *Magn Reson Med* 1999;**42**:970–8.
343. Nayak KS, Pauly JM, Kerr AB et al. Real-time color flow MRI. *Magn Reson Med* 2000;**43**:251–8.
344. Sechtem U, Pflugfelder PW, Cassidy MM et al. Mitral or aortic regurgitation: quantification of regurgitant volumes with cine MR imaging. *Radiology* 1988;**167**:425–30.
345. Globits S, Frank H, Mayr H et al. Quantitative assessment of aortic regurgitation by magnetic resonance imaging. *Eur Heart J* 1992;**13**:78–83.
346. Yoshida K, Yoshikawa J et al. Assessment of aortic regurgitation by the acceleration flow signal void proximal to the leaking orifice in cinemagnetic resonance imaging. *Circulation* 1991;**83**:1951–5.
347. Globits S, Blake L, Bourne M et al. Assessment of hemodynamic effects of ACE inhibitor therapy in chronic aortic regurgitation by using velocity encoded cine magnetic resonance imaging. *Am Heart J* 1996;**131**:289–93.
348. Hoffmann U, Frank H, Stefenelli T et al. Afterload reduction in severe aortic regurgitation. *J Magn Reson Imaging* 2001;**14**:693–7.
349. Dulce MC, Mostbeck GH, O'Sullivan M et al. Severity of aortic regurgitation: interstudy reproducibility of measurements with velocity-encoded cine MR imaging. *Radiology* 1992;**185**:235–40.
350. Chatzimavroudis GP, Walker PG, Oshinski JN et al. Slice location dependence of aortic regurgitation measurements with MR phase velocity mapping. *Magn Reson Med* 1997;**37**:545–51.
351. Nishimura T, Yamada N, Itoh A et al. Cine MR imaging in mitral regurgitation: comparison with colour Doppler flow imaging. *Am J Roentgenol* 1989;**153**:721–4.
352. Aurigemma G, Reichek N, Schiebler M et al. Evaluation of mitral regurgitation by cine magnetic resonance imaging. *Am J Cardiol* 1990;**66**:621–5.
353. Hundley WG, Li HF, Willard JE et al. Magnetic resonance imaging assessment of the severity of mitral regurgitation. Comparison with invasive techniques. *Circulation* 1995;**92**:1151–8.
354. Kizilbash AM, Hundley WG, Willett DL et al. Comparison of quantitative Doppler with magnetic resonance imaging for assessment of the severity of mitral regurgitation. *Am J Cardiol* 1998;**81**:792–4.
355. Fujita N, Chazouilleres AF, Hartiala JJ et al. Quantification of mitral regurgitation by velocity-encoded cine nuclear magnetic resonance imaging. *J Am Coll Cardiol* 1994;**23**:951–8.
356. Chatzimavroudis GP, Oshinski JN, Pettigrew RI et al. Quantification of mitral regurgitation with MR phase-velocity mapping using a control volume method. *J Magn Reson Imaging* 1998;**8**:577–82.
357. Kozerke S, Schwitter J, Pedersen EM et al. Aortic and mitral regurgitation: Quantification using moving slice velocity mapping. *J Magn Reson Imaging* 2001;**14**:106–12.
358. John AS, Dill T, Brandt RR et al. Magnetic resonance to assess the aortic valve area in aortic stenosis: how does it compare to current diagnostic standards. *J Am Coll Cardiol* 2003;**42**:519–26.
359. Kilner PJ, Manzara CC, Mohiaddin RH et al. Magnetic resonance jet velocity mapping in mitral and aortic valve stenosis. *Circulation* 1993;**87**:1239–48.
360. Caruthers SD, Lin SJ, Brown P et al. Practical value of cardiac magnetic resonance imaging for clinical quantification of aortic valve stenosis: comparison with echocardiography. *Circulation* 2003;**108**:2236–43.
361. Omran H, Schmidt H, Hackenbroch M et al. Silent and apparent cerebral embolism after retrograde catheterisation of the aortic valve in valvular stenosis: a prospective, randomised study. *Lancet* 2003;**361**:1241–6.
362. Friedrich MG, Schulz-Menger J, Poetsch T et al. Quantification of valvular aortic stenosis by magnetic resonance imaging. *Am Heart J* 2002;**144**:329–34.
363. Edwards MB, Taylor KM, Shellock FG. Prosthetic heart valves: evaluation of magnetic field interactions, heating, and artifacts at 1.5 T. *J Magn Reson Imaging* 2000;**12**:363–9.
364. Kozerke S, Hasenkam JM, Nygaard H et al. Heart motion-adapted MR velocity mapping of blood velocity distribution downstream of aortic valve prostheses: initial experience. *Radiology* 2001;**218**:548–55.
365. Bottomley PA, Weiss RG. Noninvasive magnetic resonance detection of creatine depletion in nonviable infarcted myocardium. *Lancet* 1998;**351**:714–8.
366. Reeves RC, Evanochko WT, Canby RC et al. Demonstration of increased myocardial lipid with postischemic dysfunction (''myocardial stunning) by proton nuclear magnetic resonance spectroscopy. *J Am Coll Cardiol* 1989;**13**:739–44.
367. Kim RJ, Lima JA, Chen EL et al. Fast ^{23}Na magnetic resonance imaging of acute reperfused myocardial infarction. Potential to assess myocardial viability. *Circulation* 1997;**95**:1877–85.
368. Fieno DS, Kim RJ, Rehwald WG et al. Physiological basis for potassium (39K) magnetic resonance imaging of the heart. *Circ Res* 1999;**84**:913–20.
369. Neubauer S, Krahe T, Schindler R et al. ^{31}P magnetic resonance spectroscopy in dilated cardiomyopathy and coronary artery disease. Altered cardiac high-energy phosphate metabolism in heart failure. *Circulation* 1992;**86**:1810–8.
370. de Roos A, Doornbos J, Luyten PR et al. Cardiac metabolism in patients with dilated and hypertrophic cardiomyopathy: assessment

with proton-decoupled P-31 MR spectroscopy. *J Magn Reson Imaging* 1992;**2**:711–9.
371. Hardy CJ, Weiss RG, Bottomley PA et al. Altered myocardial high-energy phosphate metabolism in patients with dilated cardiomyopathy. *Am Heart J* 1991;**122**:795–801.
372. Neubauer S, Horn M, Cramer M et al. Myocardial phosphocreatine to ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy. *Circulation* 1997;**96**:2190–6.
373. Conway MA, Allis J, Ouwerkerk R et al. Detection of low phosphocreatine to ATP ratio in failing hypertrophied human myocardium by ^{31}P magnetic resonance spectroscopy. *Lancet* 1991;**338**:973–6.
374. Weiss RG, Bottomley PA, Hardy CJ et al. Regional myocardial metabolism of high-energy phosphates during isometric exercise in patients with coronary artery disease. *N Engl J Med* 1990;**323**:1593–600.
375. Yabe T, Mitsunami K, Okada M et al. Detection of myocardial ischemia by ^{31}P magnetic resonance spectroscopy during handgrip exercise. *Circulation* 1994;**89**:1709–16.
376. Yabe T, Mitsunami K, Inubushi T et al. Quantitative measurements of cardiac phosphorus metabolites in coronary artery disease by ^{31}P magnetic resonance spectroscopy. *Circulation* 1995;**92**:15–23.
377. KalilFilho R, de Albuquerque CP, Weiss RG et al. Normal high-energy phosphate ratios in stunned human myocardium. *J Am Coll Cardiol* 1997;**30**:1228–32.
378. Fraser Jr CD, Chacko VP, Jacobus WE et al. Early phosphorus 31 nuclear magnetic resonance bioenergetic changes potentially predict rejection in heterotopic cardiac allografts. *J Heart Transplant* 1990;**9**:197–204.
379. Canby RC, Evanochko WT, Barrett LV et al. Monitoring the bioenergetics of cardiac allograft rejection using in vivo P-31 nuclear magnetic resonance spectroscopy. *J Am Coll Cardiol* 1987;**9**:1067–74.
380. Pluim BM, Chin JC, De Roos A et al. Cardiac anatomy, function and metabolism in elite cyclists assessed by magnetic resonance in aging and spectroscopy. *Eur Heart J* 1996;**17**:1271–8.
381. Rajagopalan B, Blackledge MJ, McKenna WJ et al. Measurement of phosphocreatine to ATP ratio in normal and diseased human heart by ^{31}P magnetic resonance spectroscopy using the rotating frame depth selection technique. *Ann NY Acad Sci* 1987;**508**:321–32.
382. Jung WI, Sieverding L, Breuer J et al. ^{31}P NMR spectroscopy detects metabolic abnormalities in asymptomatic patients with hypertrophic cardiomyopathy. *Circulation* 1998;**97**:2536–42.
383. Buchthal SD, den Hollander JA, Bairey et al. Abnormal myocardial phosphorus-31 nuclear magnetic resonance spectroscopy in women with chest pain but normal coronary angiograms. *N Engl J Med* 2000;**342**:829–35.
384. Berry E, Kelly S, Westwood ME et al. The cost-effectivenss of magnetic resonance angiography for carotid artery stenosis and peripheral vascular disease: a systematic review. *Health Tech Assess* 2002;**6**:1–165.
385. Mark DB, Shaw LJ, Lauer MS et al. Task force #5 – is atherosclerotic imaging cost effective? From the 34th Bethesda Conference on Atherosclerotic Imaging. *J Am Coll Cardiol* 2003;**41**:1906–17.
386. Office of Technology Assessment. The implications of cost-effectiveness analysis of medical technology, Chapters 1–4. Washington, DC: US Government Printing Office; August, 1980.
387. Mushlin AI, Ruchlin HS, Callahan MA. Cost effectiveness of diagnostic tests. *Lancet* 2001;**358**:1353–5.
388. Shaw LJ, Redberg R. From clinical trials to public health policy: the path from imaging to screening. *Am J Cardiol* 2001;**88**:62E–5E.
389. Oortwijm W, Banta HD, Cranovsky R. Introduction: mass screening, health technology assessment, and health policy in some European countries. *Int J Technol Assess Health Care* 2001;**17**(Sum-):269–74.
390. Available from: www.hcfa.gov/quality/3j2-5.htm.
391. Laupacis A, Feeny D, Detsky AS et al. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. *CMAJ* 1992;**146**:473–81.
392. Petticrew MP, Sowden AJ, Lister-Sharp D et al. False-negative results in screening programmes: systematic review of impact and implications. *Health Technol Assess* 2000;**4**:1–120.
393. Greenland P, Abrams J, Aurigemma GP et al. Prevention Conference V: Beyond secondary prevention: identifying the high-risk patient for primary prevention: noninvasive tests of Atherosclerotic burden: Writing Group III. *Circulation* 2000;**101**: E16–22.
394. Mowatt G, Bower DJ, Brebner JA et al. When and how to assess fast-changing technologies: A comparative study of medical applications of four generic technologies. *Health Tech Assess* 1997;**1**:1–151.
395. Beller GA, Bonow RO, Fuster V et al. ACC Revised Recommendations for Training in Adult Cardiovascular Medicine Core Cardiology Training II (COCATS 2) (Revision of the 1995 COCATS Training Statement); 2002. American College of Cardiology Web site. Available from http://www.acc.org/clinical/training/cocats2.pdf.
396. Hunink MG, Kuntz KM, Fleischmann KE et al. Noninvasive imaging for the diagnosis of coronary artery disease: focusing the development of new diagnostic technology. *Ann Int Med* 1999;**131**:673–80.
397. National Institute of Clinical Excellence website: http://www.nice.org.uk/Docref.asp?d=95051.
398. Marwick TH, Anderson T, Williams MJ et al. Exercise echocardiography is an accurate and cost-efficient technique for detection of coronary artery disease in women. *J Am Coll Cardiol* 1995;**26**:335–41.
399. Shaw LJ, Culler SD, Becker NR. Current evidence on cost effectiveness of noninvasive cardiac testing. In: Pohost G, O'Rourke R, Shah D, Berman D, editors. *Subsection E: analytic approaches to cost effectiveness and outcomes measurement in cardiovascular imaging, imaging in cardiovascular disease*. Philadelphia (PA): Lippincott, Williams, & Wilkins; 2000. p. 479–500.